Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
31 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 53(1); January 2021
Prev issue Next issue
Special Article
Practical Advice for South Korean Medical Researchers Regarding Open-Access and Predatory Journals
Chai Hong Rim
Cancer Res Treat. 2021;53(1):1-8.   Published online September 21, 2020
DOI: https://doi.org/10.4143/crt.2020.816
AbstractAbstract PDFSupplementary MaterialPubReaderePub
In recent decades, the volume of scholarly literature worldwide has increased significantly, and open-access publishing has become commonplace. These changes are even more dominant in South Korea. Comparing the periods of 1981-2000 and 2001-2020, the number of medical articles produced in Korea increased by 16.8 times on the Web of Science platform (13,223 to 222,771 papers). Before 1990, almost no open-access articles were produced in South Korea, but in the last 10 years open-access publications came to account for almost 40% of all South Korean publications on Web of Science. Along with the expansion of literature and the development of open-access publishing, predatory journals that seek profit without conducting quality assurance have appeared and undermined the academic corpus. In this rapidly changing environment, medical researchers have begun contemplating publication standards. In this article, recent trends in academic publishing are examined from international and South Korean perspectives, and the significance of open-access publishing and recent changes are discussed. Practical methods that can be used to select legitimate publishers, including open-access journals, and identify predatory journals are also discussed.

Citations

Citations to this article as recorded by  
  • Investigating Country-Specific Perceptions of Predatory Journals and Their Impact on Scholarly Integrity: A Systematic Review
    Alessandro Martinino, Gabriele Campagnoli, Sofia Dallavalle, Allison Soto, Sjaak Pouwels, Frank Smeenk
    Cureus.2024;[Epub]     CrossRef
  • OPEN ACCESS PUBLISHING — “SO NEAR AND YET SO FAR”
    Sham Santhanam, Mohit Goyal
    Central Asian Journal of Medical Hypotheses and Ethics.2023; 3(4): 257.     CrossRef
  • 10,496 View
  • 201 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Original Articles
Basic
TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
Cancer Res Treat. 2021;53(1):9-24.   Published online September 16, 2020
DOI: https://doi.org/10.4143/crt.2020.434
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
To find biomarkers for disease, there have been constant attempts to investigate the genes that differ from those in the disease groups. However, the values that lie outside the overall pattern of a distribution, the outliers, are frequently excluded in traditional analytical methods as they are considered to be ‘some sort of problem.’ Such outliers may have a biologic role in the disease group. Thus, this study explored new biomarker using outlier analysis, and verified the suitability of therapeutic potential of two genes (TM4SF4 and LRRK2).
Materials and Methods
Modified Tukey’s fences outlier analysis was carried out to identify new biomarkers using the public gene expression datasets. And we verified the presence of the selected biomarkers in other clinical samples via customized gene expression panels and tissue microarrays. Moreover, a siRNA-based knockdown test was performed to evaluate the impact of the biomarkers on oncogenic phenotypes.
Results
TM4SF4 in lung cancer and LRRK2 in breast cancer were chosen as candidates among the genes derived from the analysis. TM4SF4 and LRRK2 were overexpressed in the small number of samples with lung cancer (4.20%) and breast cancer (2.42%), respectively. Knockdown of TM4SF4 and LRRK2 suppressed the growth of lung and breast cancer cell lines. The LRRK2 overexpressing cell lines were more sensitive to LRRK2-IN-1 than the LRRK2 under-expressing cell lines
Conclusion
Our modified outlier-based analysis method has proved to rescue biomarkers previously missed or unnoticed by traditional analysis showing TM4SF4 and LRRK2 are novel target candidates for lung and breast cancer, respectively.

Citations

Citations to this article as recorded by  
  • TM4SF19—A New Biomarker for Diagnosis and Prognosis of Bladder Urothelial Carcinoma
    蕴博 刘
    Advances in Clinical Medicine.2024; 14(02): 3616.     CrossRef
  • Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking
    Qian Zhang, Dengfeng Chen
    Drug Development Research.2024;[Epub]     CrossRef
  • DeepDRA: Drug repurposing using multi-omics data integration with autoencoders
    Taha Mohammadzadeh-Vardin, Amin Ghareyazi, Ali Gharizadeh, Karim Abbasi, Hamid R. Rabiee, Amgad Muneer
    PLOS ONE.2024; 19(7): e0307649.     CrossRef
  • TM4SF4 is a diagnostic biomarker accelerating progression of papillary thyroid cancer via AKT pathway
    Lizhi Lin, Jialiang Wen, Tiansheng Xu, Yuhao Si
    Cancer Biology & Therapy.2024;[Epub]     CrossRef
  • Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance
    Nur Syafiqah Rahim, Yuan Seng Wu, Maw Shin Sim, Appalaraju Velaga, Srinivasa Reddy Bonam, Subash C. B. Gopinath, Vetriselvan Subramaniyan, Ker Woon Choy, Sin-Yeang Teow, Ismail M. Fareez, Chandramathi Samudi, Shamala Devi Sekaran, Mahendran Sekar, Rhanye
    Pharmaceuticals.2023; 16(1): 110.     CrossRef
  • Quantitative Analysis on Molecular Characteristics Evolution of Gastric Cancer Progression and Prognosis
    Yeting Hu, Xiaoqin Lv, Wenwu Wei, Xiang Li, Kaixuan Zhang, Linlin Zhu, Tao Gan, Hongjuan Zeng, Jinlin Yang, Nini Rao
    Advanced Biology.2023;[Epub]     CrossRef
  • Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis
    Muttanagouda Giriyappagoudar, Basavaraj Vastrad, Rajeshwari Horakeri, Chanabasayya Vastrad
    Biomedicines.2023; 11(12): 3109.     CrossRef
  • Parkinson’s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender
    Joon Yan Selene Lee, Jing Han Ng, Seyed Ehsan Saffari, Eng-King Tan
    Aging.2022; 14(5): 2148.     CrossRef
  • Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis
    Zhisong Yang, Li Zhou, Haiyan Ge, Weimin Shen, Lin Shan
    Open Medicine.2022; 17(1): 1148.     CrossRef
  • LncRNA ST8SIA6-AS1 facilitates hepatocellular carcinoma progression by governing miR-651-5p/TM4SF4 axis
    Yanjie Mou, Xiaoming Ding
    Anti-Cancer Drugs.2022; 33(8): 741.     CrossRef
  • Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
    Mingfeng Yu, Yi Long, Yuchao Yang, Manjun Li, Theodosia Teo, Benjamin Noll, Stephen Philip, Shudong Wang
    European Journal of Medicinal Chemistry.2021; 218: 113391.     CrossRef
  • Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis
    Ka-Won Noh, Reinhard Buettner, Sebastian Klein
    Biomolecules.2021; 11(9): 1310.     CrossRef
  • 11,178 View
  • 371 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
General
Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients
Jung Hye Kwon, Sun Kyung Baek, Do Yeun Kim, Yu Jung Kim, Myung Ah Lee, Hye Jin Choi, Ja Min Byun, Jin Young Jeong, Sam H Ahmedzai, Geun-Doo Jang
Cancer Res Treat. 2021;53(1):25-31.   Published online August 31, 2020
DOI: https://doi.org/10.4143/crt.2020.235
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to validate the Sheffield Profile for Assessment and Referral to Care (SPARC) as an effective tool for screening palliative care needs among Korean cancer patients.
Materials and Methods
The English version of the SPARC was translated by four Korean oncologists and reconciled by a Korean language specialist and a medical oncologist fluent in English. After the first version of the Korean SPARC (K-SPARC) was developed, back-translation into English was performed by a professional translator and bilingual oncologist. The back-translated version was reviewed by the original author (S.H.A.), and modifications were made (ver. 2). The second version of the K-SPARC was tested against other questionnaires, including the Functional Assessment of Cancer Therapy-General (FACT-G) and the Edmonton Symptom Assessment System (ESAS).
Results
Thirty patients were enrolled in the pilot trial. Fifteen were male, and the median age was 64.5 years. Six patients had an Eastern Cooperative Oncology Group performance status of 2 or more. All patients except one were receiving chemotherapy. Regarding internal consistency, the Cronbach’s α scores for physical symptoms, psychological issues, religious and spiritual issues, independency and activity, family and social issues, and treatment issues were 0.812, 0.804, 0.589, 0.843, 0.754, and 0.822, respectively. The correlation coefficients between the SPARC and FACT-G were 0.479 (p=0.007) for the physical domain and –0.130 (p=0.493) for the social domain.
Conclusion
This pilot study indicates that the K-SPARC could be a reliable tool to screen for palliative care needs among Korean cancer patients. A further study to validate our findings is ongoing.

Citations

Citations to this article as recorded by  
  • Translation and linguistic validation of the Sheffield Profile for Assessment and Referral for Care (SPARC) to Colombian Spanish
    Socorro Moreno, Cindy V. Mendieta, Esther de Vries, Sam H. Ahmedzai, Karen Rivera, Camilo Cortes-Mora, Jose A. Calvache
    Palliative and Supportive Care.2024; : 1.     CrossRef
  • Validation of traditional Chinese version of Sheffield Profile for Assessment and Referral for Care Questionnaire in Taiwanese patients
    Ming-Chieh Tsai, Yun-Yun Chou, El-Wui Loh, Ashleigh Peng Lin, Hsueh-Chi Wu, Li-Sin Hsiao, Chia-Li Chang, Shu-Fen Chen, Sam H. Ahmedzai, Ka-Wai Tam
    Journal of the Chinese Medical Association.2024; 87(1): 58.     CrossRef
  • Validation of the Spanish translation Sheffield Profile for Assessment and Referral for Care (SPARC-Sp) at the Hospital Universitario San Jose of Popayan, Colombia
    Cindy V. Mendieta, Jose A. Calvache, Martín A. Rondón, Carlos Javier Rincón-Rodríguez, Sam H. Ahmedzai, Esther de Vries
    Palliative and Supportive Care.2024; : 1.     CrossRef
  • Co-Designing a Strategy for Implementing the SPARC Holistic Needs Assessment Tool in the Colombian Clinical Context
    Cindy V. Mendieta, Esther de Vries, Jose Andrés Calvache, Sam H. Ahmedzai, Gillian Prue, Tracey McConnell, Joanne Reid
    Healthcare.2023; 11(22): 2917.     CrossRef
  • Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol
    Cinzia Brunelli, Ernesto Zecca, Alessandra Pigni, Paola Bracchi, Mariangela Caputo, Silvia Lo Dico, Viviana Fusetti, Antonino Tallarita, Cristiana Bergamini, Marta Brambilla, Alessandra Raimondi, Monica Niger, Salvatore Provenzano, Pierangela Sepe, Sara A
    BMJ Open.2022; 12(10): e059410.     CrossRef
  • Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study
    Jeehee Pyo, Minsu Ock, Mina Lee, Juhee Kim, Jaekyung Cheon, Juhee Cho, Jung Hye Kwon, Hyeyeoung Kim, Hyeon-Su Im, Young Joo Min, Su-Jin Koh
    BMC Palliative Care.2021;[Epub]     CrossRef
  • 7,547 View
  • 162 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016
Meerim Park, Jiwon Lim, Jun Ah Lee, Byung Kiu Park, Kyu-Won Jung, Young-Joo Won, Hyeon Jin Park
Cancer Res Treat. 2021;53(1):32-44.   Published online October 5, 2020
DOI: https://doi.org/10.4143/crt.2020.644
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated the incidence and relative survival rates (RSRs) for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in Korea
Materials and Methods
Data from the Korea Central Cancer Registry were used to calculate percent distributions, age-specific incidence rates, age-standardized incidence rates (ASRs) per million, annual percent changes (APCs), average APCs, and RSRs for cancers diagnosed in AYAs.
Results
ASR of all cancers among AYAs was 654.5 per million. The largest diagnosed group of cancers was carcinomas (almost 80%). Crude incidence increased with age, from 170.4 per million for those aged 15-19 years to 1,639.8 per million for those aged 35-39 years. ASR increased from 414.8 per million to 820.4 per million, with an APC of 9.0%. The incidence of thyroid carcinoma showed the most rapid increment (APC, 14.0%), followed by non-Hodgkin lymphoma (APC, 13.4%). The 5-year RSR among AYAs significantly improved from 62.1% to 90.8%. Survival improvement in AYAs was higher than that in children but lower than that in older adults (APC, 2.1% vs. 1.9% vs. 3.1%). The most marked survival improvement was found for leukemia and lymphoma. Astrocytoma, rhabdomyosarcoma, and carcinoma of the trachea, bronchus, and lung had a 5-year RSR of < 50%.
Conclusion
There was an improvement in cancer survivals in AYAs, comparable to that achieved in children. However, survivals in several cancer types do not appear to be improving. Further research focusing on the epidemiology and therapeutic strategies for cancers in AYAs is needed.

Citations

Citations to this article as recorded by  
  • Research progress in the application of radiotherapy in the treatment of pediatric tumors
    Z-H. Wang, Y. Liu, J-Q. Guo, H-L. Liang, W-W. Zhi
    International Journal of Radiation Research.2024; 22(1): 65.     CrossRef
  • Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults
    Mustafa Wasifuddin, Nosakhare Paul Ilerhunmwuwa, Henry Becerra, Narek Hakobyan, Neharika Shrestha, Ifeanyi Nnamdi Uche, Htet Lin, Hesham Abowali, Jin Zheng, Ruchi Yadav, Akriti Pokhrel, Ladan Enayati, Mitchell Hare, Rohan Hehr, Khrystyna Kozii, Bulat Giba
    European Journal of Haematology.2024; 113(4): 454.     CrossRef
  • Perception of Korean healthy adolescents on cancer and adolescent cancer survivors: a cross-sectional survey
    Min Kyung Hyun, Yeonseung Lee, Hyun Jeong Lee, Young Ae Kim
    BMC Public Health.2024;[Epub]     CrossRef
  • Psychometric Evaluation of the Spiritual Perspective Scale for Adolescents and Young Adults with Cancer
    Chin-Mi Chen, Heeyeon Son, Yvonne Yueh-Feng Lu, Li-Min Wu
    Asia-Pacific Journal of Oncology Nursing.2024; : 100594.     CrossRef
  • Development and evaluation of the feasibility, validity, and reliability of a screening tool for determining distress and supportive care needs of adolescents and young adults with cancer in Japan
    Takatoshi Hirayama, Maiko Fujimori, Yuko Yanai, Hiroto Ishiki, Akie Shindo, Moeko Tanaka, Tomomi Kobayashi, Rebekah Kojima, Eriko Satomi
    Palliative and Supportive Care.2023; 21(4): 677.     CrossRef
  • Five-year Survival Trends for Young Adult Cancers Diagnosed from 2002 to 2014 in Taiwan and the United States
    Yu-Han Tsai, Yu-Tung Teng, Tai-Chuan Kuan, Jason J. Liu
    Cancer Epidemiology, Biomarkers & Prevention.2023; 32(6): 834.     CrossRef
  • Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019
    Chenyu Luo, Na Li, Bin Lu, Jie Cai, Ming Lu, Yuhan Zhang, Hongda Chen, Min Dai
    Chinese Medical Journal.2022; 135(1): 42.     CrossRef
  • Fertility‐sparing surgery for early‐stage cervical cancer: A case series study on the efficacy and feasibility of cervical conization followed by pelvic lymphadenectomy
    Mayuko Yamamoto, Takeshi Motohara, Yutaka Iwagoi, Shingo Tayama, Hironori Tashiro, Eiji Kondoh, Hidetaka Katabuchi
    Journal of Obstetrics and Gynaecology Research.2022; 48(6): 1444.     CrossRef
  • Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016
    Hsin Wang, Yu-Han Tsai, Yaa-Hui Dong, Jason J. Liu
    Cancer Epidemiology.2022; 78: 102144.     CrossRef
  • Osteosarcoma in Adolescents and Young Adults
    Jun Ah Lee, Jiwon Lim, Hye Young Jin, Meerim Park, Hyeon Jin Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, Young-Joo Won
    Cells.2021; 10(10): 2684.     CrossRef
  • 7,932 View
  • 209 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Head/neck cancer
Development of a Tongue Immobilization Device Using a 3D Printer for Intensity Modulated Radiation Therapy of Nasopharyngeal Cancer Patients
Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Seung Gyu Park, Yoo-mi Choi, Cho Hee Na, Chae-Seon Hong, Dongryul Oh, Dong Yeol Kwon, Cheol Chong Kim, Dong Hyeon Kim
Cancer Res Treat. 2021;53(1):45-54.   Published online September 15, 2020
DOI: https://doi.org/10.4143/crt.2020.572
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to reduce radiation doses to the tongue, a patient-specific semi-customized tongue immobilization device (SCTID) was developed using a 3D printer for helical tomotherapy (HT) of nasopharyngeal cancer (NPCa). Dosimetric characteristics and setup stability of the SCTID were compared with those of a standard mouthpiece (SMP).
Materials and Methods
For displacement and robust immobilization of the tongue, the SCTID consists of four parts: upper and lower tooth stoppers, tongue guider, tongue-tip position guide bar, and connectors. With the SCTID and SMP, two sets of planning computed tomography and HT plans were obtained for 10 NPCa patients. Dosimetric and geometric characteristics were compared. Position reproducibility of the tongue with SCTID was evaluated by comparing with planned dose and adaptive accumulated dose of the tongue and base of the tongue based on daily setup mega-voltage computed tomography.
Results
Using the SCTID, the tongue was effectively displaced from the planning target volume compared to the SMP. The median mucosa of the tongue (M-tongue) dose was significantly reduced (20.7 Gy vs. 27.8 Gy). The volumes of the M-tongue receiving a dose of 15 Gy, 30 Gy, and 45 Gy and the volumes of the mucosa of oral cavity and oropharynx (M-OC/OP) receiving a dose of 45 Gy and 60 Gy were significantly lower than using the SMP. No significant differences was observed between the planned dose and the accumulated adaptive dose in any dosimetric characteristics of the tongue and base of tongue.
Conclusion
SCTID can not only reduce the dose to the M-tongue and M-OC/OP dramatically, when compared to SMP, but also provide excellent reproducibility and easy visual verification.

Citations

Citations to this article as recorded by  
  • A Novel Immobilization Method for the Treatment of Head and Neck Cancer Using 3D Printing
    Christopher Szewczyk, Yixiang Liao, Samer Al-Khudari, Michael J. Jelinek, Ken Tatebe
    Practical Radiation Oncology.2024; 14(1): 20.     CrossRef
  • Novel tongue-positioning device to reduce tongue motions during radiation therapy for head and neck cancer: Geometric and dosimetric evaluation
    Seongmoon Jung, Bitbyeol Kim, Sung Young Lee, Won Ick Chang, Jaeman Son, Jong Min Park, Chang Heon Choi, Joo Ho Lee, Hong-Gyun Wu, Jung-in Kim, Jin Ho Kim, Minsoo Chun
    PLOS ONE.2023; 18(9): e0291712.     CrossRef
  • Dosimetric comparison between VMAT plans using the fast-rotating O-ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma
    Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Jin Man Kim, Dong Yeol Kwon, Byoung Suk Park, Kyungmi Yang
    Radiation Oncology.2022;[Epub]     CrossRef
  • Tongue Displacement Device in Decreasing the Radiation Dose to Tongue and Preventing Proton Beam Overshoot in Proton Therapy for Unilateral Head and Neck Cancer
    Chae-Seon Hong, Dongryul Oh, Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Seyjoon Park, Woojin Lee
    Frontiers in Physics.2021;[Epub]     CrossRef
  • 8,396 View
  • 245 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Breast cancer
Impact of Awareness of Breast Density on Perceived Risk, Worry, and Intentions for Future Breast Cancer Screening among Korean Women
Anh Thi Ngoc Tran, Ji Hae Hwang, Eunji Choi, Yun Yeong Lee, Mina Suh, Chan Wha Lee, Yeol Kim, Kui Son Choi
Cancer Res Treat. 2021;53(1):55-64.   Published online August 18, 2020
DOI: https://doi.org/10.4143/crt.2020.495
AbstractAbstract PDFPubReaderePub
Purpose
This study sought to examine perceived risk and concerns for breast cancer according to awareness of breast density and states thereof among Korea women and to identify the impact of such awareness on screening intentions.
Materials and Methods
This study was based on the 2017 Korean National Cancer Screening Survey of a nationally representative and randomly selected sample of Koreans. Ordinal logistic regression was conducted to examine associations for awareness of and knowledge on breast density in relation to psychological factors. Multivariate logistic regression analyses were conducted to investigate significant factors associated with intentions to undergo breast cancer screening.
Results
Among a total of 1,609 women aged 40-69 years, 62.0% were unaware of their breast density, and only 29.7% had good breast density knowledge. Awareness of one’s breast density and knowledge about breast density were positively associated with perceptions of absolute and comparative risk and cancer worry. Women aware of their breast density (adjusted odds ratio [aOR], 1.35 for women aware of having a non-dense breast; aOR, 4.17 for women aware of having a dense breast) and women with a good level of breast density knowledge (aOR, 1.65) were more likely to undergo future breast cancer screening.
Conclusion
Breast density awareness and knowledge showed positive associations with psychological factors and breast cancer screening intentions. However, the majority of Korean women were not aware of their breast density status and demonstrated poor knowledge about breast density. These results demonstrate a need for better health communication concerning breast density.

Citations

Citations to this article as recorded by  
  • The triad of knowledge, regular medical consultation, and recommendations for enhanced breast cancer screening intention in Morocco
    Nadia Ouzennou, Mohamed Aboufaras, Nezha Nacer, Hicham Mejdouli, Jaouad Chouikh, Samia Rkha
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Awareness of Breast Cancer Risk Factors in Women with vs. Without High Breast Density
    Jan Endrikat, Gilda Schmidt, Bhagyashree Oak, Viplav Shukla, Prakirti Nangia, Nicolas Schleyer, John Crocker, Ruud Pijnapppel
    Patient Preference and Adherence.2024; Volume 18: 1577.     CrossRef
  • Public awareness, specific knowledge, and worry about mpox (monkeypox): A preliminary community-based study in Shenzhen, China
    Fangmei Ren, Junchao Liu, Jianping Miao, Yucheng Xu, Ruiyin Zhang, Jingjie Fan, Wei Lin
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Understanding of Dense Breast and Perception of Breast Cancer Risk of Nurses with or without Dense Breast Notification
    Seon Mi Yoon, Jeong Hee Kang
    Asian Oncology Nursing.2023; 23(2): 75.     CrossRef
  • Survey of knowledge and awareness of breast density amongst Maltese Women undergoing mammography screening
    S.L. Gauci, J.G. Couto, D. Mizzi
    Radiography.2023; 29(5): 911.     CrossRef
  • Anticipatory anxiety and participation in cancer screening. A systematic review
    Belinda Goodwin, Laura Anderson, Katelyn Collins, Saira Sanjida, Marcos Riba, Gursharan K. Singh, Kimberley M. Campbell, Heather Green, Sana Ishaque, Alastair Kwok, Melissa J. Opozda, Amy Pearn, Joanne Shaw, Ursula M. Sansom‐Daly, Joanna M. Tsirgiotis, Mo
    Psycho-Oncology.2023; 32(12): 1773.     CrossRef
  • Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer
    Ji Soo Park, Saeam Shin, Yoon Jung Lee, Seung-Tae Lee, Eun Ji Nam, Jung Woo Han, Sun Hwa Lee, Tae Il Kim, Hyung Seok Park
    Cancer Research and Treatment.2022; 54(4): 1099.     CrossRef
  • Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality
    Eunji Choi, Jae Kwan Jun, Mina Suh, Kyu-Won Jung, Boyoung Park, Kyeongmin Lee, So-Youn Jung, Eun Sook Lee, Kui Son Choi
    npj Breast Cancer.2021;[Epub]     CrossRef
  • General practitioners’ (GPs) understanding and views on breast density in Australia: a qualitative interview study
    Brooke Nickel, Hankiz Dolan, Stacy Carter, Nehmat Houssami, Meagan Brennan, Jolyn Hersch, Alia Kaderbhai, Kirsten McCaffery
    BMJ Open.2021; 11(8): e047513.     CrossRef
  • 6,683 View
  • 134 Download
  • 9 Crossref
Close layer
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients
Mihong Choi, Jiyeon Han, Bo Ram Yang, Myoung-jin Jang, Miso Kim, Dae-Won Lee, Tae-Yong Kim, Seock-Ah Im, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee
Cancer Res Treat. 2021;53(1):65-76.   Published online September 23, 2020
DOI: https://doi.org/10.4143/crt.2020.430
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer.
Materials and Methods
We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer.
Results
Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)–negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05).
Conclusion
Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies.

Citations

Citations to this article as recorded by  
  • Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
    Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
    Expert Review of Anticancer Therapy.2024; 24(6): 435.     CrossRef
  • Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis
    Xiaolin Jia, Ye Lu, Zili Xu, Qingqing Mu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Effect of statins use on risk and prognosis of breast cancer: a meta-analysis
    Guodong Zhao, Yanjun Ji, Qing Ye, Xin Ye, Guanqun Wo, Xi Chen, Xinyi Shao, Jinhai Tang
    Anti-Cancer Drugs.2022; 33(1): e507.     CrossRef
  • Studying the Cytotoxic Activity of Newly Designed and Synthesized HDAC Inhibitors Derivatives of Pentanoyl Anilide‐5‐Biguanide
    Othman Makki Sagheer, Mohammed Hassan Mohammed, Jaafar S. Wadi, Zaid O. Ibraheem
    Macromolecular Symposia.2022;[Epub]     CrossRef
  • Metformin and Breast Cancer: Where Are We Now?
    Mónica Cejuela, Begoña Martin-Castillo, Javier A. Menendez, Sonia Pernas
    International Journal of Molecular Sciences.2022; 23(5): 2705.     CrossRef
  • Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression
    Giorgia Centonze, Dora Natalini, Alessio Piccolantonio, Vincenzo Salemme, Alessandro Morellato, Pietro Arina, Chiara Riganti, Paola Defilippi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Synthesis of gamma biguanides butyric acid analogues as HDAC inhibitors and studying their cytotoxic activity
    Othman Makki Sagheer, Mohammed Hassan Mohammed, Zaid O. Ibraheem, Jaafar S. Wadi, Mustafa F. Tawfeeq
    Materials Today: Proceedings.2021; 47: 5983.     CrossRef
  • Statins: a repurposed drug to fight cancer
    Wen Jiang, Jin-Wei Hu, Xu-Ran He, Wei-Lin Jin, Xin-Yang He
    Journal of Experimental & Clinical Cancer Research.2021;[Epub]     CrossRef
  • Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
    Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
    International Journal of Clinical Oncology.2021; 26(11): 2004.     CrossRef
  • 8,768 View
  • 207 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Lung cancer
Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis
Jongheon Jung, Hyae Young Kim, Dong-Gil Kim, Seog Yun Park, A Ra Ko, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Youngjoo Lee
Cancer Res Treat. 2021;53(1):77-86.   Published online August 6, 2020
DOI: https://doi.org/10.4143/crt.2020.543
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate the effect of sequential therapeutic administration on the incidence of pneumonitis.
Materials and Methods
In this retrospective study, 242 patients were included. Serial radiologic findings taken during and immediately after ICI treatment were reviewed. Factors that increased pneumonitis and the relationship between peri-ICI chemotherapy and the development of pneumonitis were evaluated.
Results
Pneumonitis developed in 23 patients (9.5%); severe pneumonitis (grade ≥ 3) occurred in 13 of 23 patients (56%); pneumonitis-related death occurred in six. High-dose thoracic radiation (≥ 6,000 cGy) revealed a tendency toward high risk of pneumonitis (odds ratio, 2.642; 95% confidence interval, 0.932 to 7.490; p=0.068). Among 149 patients followed for ≥ 8 weeks after the final ICI dose, more patients who received targeted agents within 8-weeks post-ICI experienced pneumonitis (3/16, 18.8%) compared with patients who received cytotoxic agents (4/54, 7.4%) or no chemotherapy (4/79, 5.1%) (p=0.162). Targeted therapy was associated with earlier-onset pneumonitis than treatment with cytotoxic agents (35 vs. 62 days post-ICI, p=0.007); the resulting pneumonitis was more severe (grade ≥ 3, 100% vs. 0%, p=0.031).
Conclusion
Sequential administration of small-molecule targeted agents immediately after ICI may increase the risk of severe pneumonitis. The sequence of chemotherapy regimens that include ICI and targeted agents should be carefully planned to reduce the risk of pneumonitis in lung cancer patients.

Citations

Citations to this article as recorded by  
  • Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
    Anne-Laure Désage, Michael Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid, Pierre Fournel, Thomas Pierret
    Cancer Treatment Reviews.2024; 129: 102805.     CrossRef
  • Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer
    M. Cheng, R. Lin, N. Bai, Y. Zhang, H. Wang, M. Guo, X. Duan, J. Zheng, Z. Qiu, Y. Zhao
    Clinical Radiology.2023; 78(5): e377.     CrossRef
  • Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
    Qi Liu, Chenan Zhang, Yue Huang, Ruihao Huang, Shiew-Mei Huang, Erin Larkins, Liza Stapleford, Donna R. Rivera, Paul G. Kluetz, Shenggang Wang, Hao Zhu, James Weese, Elizabeth Cromartie, Mahder Teka, Sheetal Walters, Frank Wolf, Thomas D. Brown
    Cancer Research Communications.2023; 3(2): 258.     CrossRef
  • Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
    Yi-Pu Zhao, Yong Long
    Current Medical Research and Opinion.2022; 38(8): 1369.     CrossRef
  • Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Yuxuan Hao, Xiaoye Zhang, Li Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
    Norbert Banyi, Deepu Alex, Curtis Hughesman, Kelly McNeil, Diana N. Ionescu, Carmen Ma, Stephen Yip, Barbara Melosky
    Current Oncology.2022; 29(10): 7900.     CrossRef
  • Sequential or combined immune checkpoint inhibitors and targeted therapy: Navigating uncharted waters
    K. El Husseini, M. Wislez
    Respiratory Medicine and Research.2021; 79: 100820.     CrossRef
  • Multiple drugs

    Reactions Weekly.2021; 1863(1): 255.     CrossRef
  • Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway
    Jeong Hun Kim, Won Suk Lee, Hye Jin Lee, Hannah Yang, Seung Joon Lee, So Jung Kong, Soyeon Je, Hyun-Jin Yang, Jongsun Jung, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim
    OncoImmunology.2021;[Epub]     CrossRef
  • 7,691 View
  • 199 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
Mihong Choi, Heung Tae Kim, Ji-Youn Han, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Hye Jin Won, Jin Soo Lee, Youngjoo Lee
Cancer Res Treat. 2021;53(1):87-92.   Published online August 13, 2020
DOI: https://doi.org/10.4143/crt.2020.741
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Squamous cell carcinomas (SqCC) of the lung often express high levels of thymidylate synthase (TS), which is associated with primary resistance to pemetrexed. We explored the efficacy of pemetrexed in a selected population of patients with lung SqCC with low TS expression.
Materials and Methods
In this single-arm phase II trial, we enrolled 32 previously-treated patients with advanced lung SqCC exhibiting low immunohistochemical staining for TS (i.e., in 10% or less of tumor cells). The primary endpoint was 12-week progression-free survival (PFS) rate.
Results
Of 32 patients, eight patients (25%) had an Eastern Cooperative Oncology Group performance status of 2, and seven patients (22%) had previously received three or more lines of chemotherapy. The disease control rate from pemetrexed treatment was 30%, and no objective response was observed. The 12-week PFS rate was 24.5% (95% confidence interval [CI], 13.0 to 46.1). Median PFS was 1.3 months (95% CI, 1.3 to 2.7), and median overall survival was 11.8 months (95% CI, 8.1 to not applicable). Most of adverse events were grade 1 or 2.
Conclusion
Pemetrexed demonstrated modest activity as a salvage chemotherapy in patients with advanced lung SqCC with low TS expression, although its toxicity was generally manageable.
  • 6,800 View
  • 127 Download
Close layer
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat. 2021;53(1):93-103.   Published online September 21, 2020
DOI: https://doi.org/10.4143/crt.2020.459
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in previously untreated patients with metastatic non–small cell lung carcinoma (NSCLC) harboring activating EGFR mutations in circulating tumor DNA (ctDNA) as well as tumor DNA.
Materials and Methods
Patients with activating EGFR mutations in their tumor DNA underwent screening with ctDNA analysis using Mutyper and Cobas v2 assays. Enrolled subjects received osimertinib 80 mg, once daily. Primary endpoint was objective response rate (ORR) and secondary endpoints were ctDNA test sensitivity, progression-free survival (PFS), duration of response (DoR), and safety.
Results
Among 39 screened patients, 29 were ctDNA positive for activating EGFR mutations and 19 were enrolled (ex19del, n=11; L858R/L861Q, n=7; G719A, n=1). Median age was 70 and most patients had brain metastases (15/19, 79%). ctDNA test sensitivity for activating EGFR mutations was 74% using both methods and 62% (Mutyper) or 64% (Cobas v2) for individual methods. ORR was 68% (13/19), median PFS was 11.1 months (95% confidence interval [CI], 0.0 to 26.7), and median DoR was 17.6 months (95% CI, 3.5 to 31.7). ORR and median PFS were significantly superior with ex19del (91%; 21.9 months; 95% CI, 5.5 to 38.3) than with L858R/L861Q (43%; 5.1 months; 95% CI, 2.3 to 7.9). One patient discontinued the drug because of drug-related interstitial pneumonitis.
Conclusion
Osimertinib had favorable efficacy in the first-line treatment of metastatic NSCLC harboring activating EGFR mutations in ctDNA as well as tumor DNA.

Citations

Citations to this article as recorded by  
  • Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
    Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro
    Expert Opinion on Emerging Drugs.2024; 29(2): 139.     CrossRef
  • Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
    Juan Carlos Restrepo, Darly Martínez Guevara, Andrés Pareja López, John Fernando Montenegro Palacios, Yamil Liscano
    Cancers.2024; 16(13): 2338.     CrossRef
  • ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer
    Bin Liu, Bingtian Zhao, Yan Yin, Yan Jiang, Xue Feng, Lei Wang, Liang Zhai, Guangxin Liu, Dongsheng Shi, Jianwen Qin
    Cancer Management and Research.2024; Volume 16: 1405.     CrossRef
  • Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
    Yi-Ze Li, Sheng-Nan Kong, Yun-Peng Liu, Yue Yang, Hong-Mei Zhang
    Journal of Clinical Medicine.2023; 12(4): 1438.     CrossRef
  • Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
    Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana-Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris A. Charalambous, Amanda Psyrri, Emily Tsaroucha, Ioannis Boukovinas, Anna Koumarianou, Dora Hatzidaki, Evi Lianidou, Vassilis Georgouli
    Cancers.2022; 14(6): 1574.     CrossRef
  • 8,035 View
  • 220 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2021;53(1):104-111.   Published online October 5, 2020
DOI: https://doi.org/10.4143/crt.2020.894
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
As the aging of society progresses, the proportion of extremely older lung cancer patients has also increased; However, studies of these patients with non–small cell lung cancer are limited. Therefore, we investigated the initial treatment modalities and survival outcomes for patients aged 80 years or over.
Materials and Methods
We included a multicenter retrospective cohort from the Korean Association for Lung Cancer Registry, which surveys 10% of the newly diagnosed lung cancer patients across 52 hospitals in Korea. We analyzed and compared the 2014–2016 data of the non–small cell lung cancer patients aged ≥ 80 years and those aged < 80 years.
Results
Of the 6,576 patients reviewed, 780 patients were aged ≥ 80 years, and 5,796 patients were aged < 80 years. In the patients aged ≥ 80 years, surgery and radiation therapy resulted in longer patient survival among those with a resectable tumor (stage I–II) than the best supportive care (median survival, not reached [surgery] vs. 32.2 months [radiation therapy] vs. 11.43 months [best supportive care]). The duration of survival in patients with advanced-stage (IV) lung cancers was higher after chemotherapy than after the best supportive care (median survival, 8.63 months vs. 2.5 months). Patients with stage IV adenocarcinoma who received targeted therapy had better survival than those who did not (median survival, 9.0 months vs. 4.3 months).
Conclusion
Even in extremely older patients, active treatments, such as surgery, radiation therapy, and chemotherapy, can result in better survival outcomes than the best supportive care.

Citations

Citations to this article as recorded by  
  • ADENOCARCINOMA PULMONAR - ASPECTOS EPIDEMIOLÓGICOS, FISIOPATOLÓGICOS E TERAPÊUTICOS
    Marcelo Vinicius Pereira Silva, Elizeu Augusto de Freitas Junior, Allan Martins de Oliveira, Elaine Timm, Mariana Brito Siqueira, Mônica Stefany Martelli, Elielson Mendonça de Oliveira, Victor Cavalcante Machado, Igor Vinicius Barbino Ferrari, Pamella Hag
    Revista Contemporânea.2024; 4(5): e4464.     CrossRef
  • Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
    Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2022; 13(9): 1349.     CrossRef
  • Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
    Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
    BMC Pulmonary Medicine.2022;[Epub]     CrossRef
  • 6,497 View
  • 146 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Gastrointestinal cancer
Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma
Yilin Tong, Yanmei Zhu, Yan Zhao, Zexing Shan, Dong Liu, Jianjun Zhang
Cancer Res Treat. 2021;53(1):112-122.   Published online August 10, 2020
DOI: https://doi.org/10.4143/crt.2020.516
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Tumor regression grade (TRG) has been widely used in gastrointestinal carcinoma to assess pathological responses to neoadjuvant chemotherapy (NCT). There are various standards without a consensus, and it is still unclear which kind of system has better predictive value. This study aims to investigate and compare the predictive ability of the Mandard and Becker TRGs in patients with locally advanced gastric cancer.
Materials and Methods
A total of 290 patients with locally advanced gastric adenocarcinoma who underwent NCT and curative surgery were studied. Survival analysis for overall survival (OS) and disease-free survival (DFS) were based on the Kaplan-Meier method and Cox proportional hazards method. Predictive values of TRGs and models were assessed by time-dependent receiver operating characteristic (ROC) curve, the area under the ROC curve (AUC), nomogram, and calibration curve.
Results
In multivariable analysis, the Mandard TRG was associated with OS (hazard ratio [HR], 1.806; p=0.026) and DFS (HR, 1.792; p=0.017). The Becker TRG was also related to OS (HR, 1.880; p=0.014) and DFS (HR, 1.919; p=0.006). The Mandard and Becker TRG AUCs for 5-year survival were 0.72 and 0.71, respectively. The whole models showed an increased predictive value, with AUCs of 0.85 and 0.86, respectively. There was no significant difference between the two TRGs and two models.
Conclusion
TRG was an independent predictor for survival, and there was no significant difference between these two systems.

Citations

Citations to this article as recorded by  
  • Microsatellite instability in gastric cancer: An institutional case series analysis in patients treated with neoadjuvant therapy
    Laura Lorenzon, Alberto Biondi, Gloria Santoro, Annamaria Agnes, Antonio Laurino, Antonia Strippoli, Riccardo Ricci, Roberto Persiani, Domenico D'Ugo
    Clinical Surgical Oncology.2024; 3(1): 100031.     CrossRef
  • The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer
    Colum Dennehy, Alisha F. Khan, Ali H. Zaidi, Vincent K. Lam
    Cancers.2024; 16(2): 286.     CrossRef
  • Evaluating Treatment Response in GEJ Adenocarcinoma
    Markus Graf, Joshua Gawlitza, Marcus Makowski, Felix Meurer, Thomas Huber, Sebastian Ziegelmayer
    Investigative Radiology.2024; 59(8): 583.     CrossRef
  • Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients
    Jingjing Zhang, Qiang Zhang, Bo Zhao, Gaofeng Shi
    Abdominal Radiology.2024; 49(11): 3780.     CrossRef
  • Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma
    Magnus Kock am Brink, Laura Sophie Dunst, Hans-Michael Behrens, Sandra Krüger, Thomas Becker, Christoph Röcken
    British Journal of Cancer.2023; 128(2): 375.     CrossRef
  • Time to Surgery does not Affect Oncologic Outcomes in Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: A Meta-Analysis
    Zining Liu, Zhening Zhang, Hua Liu, Junbing Chen
    Future Oncology.2023; 19(5): 397.     CrossRef
  • Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
    Alina Desiree Sandø, Reidun Fougner, Elin Synnøve Røyset, Hong Yan Dai, Jon Erik Grønbech, Erling Audun Bringeland
    Cancers.2023; 15(8): 2318.     CrossRef
  • Profiling complete regression after pre-operative therapy in gastric cancer patients using clinical and pathological data
    Alberto Biondi, Laura Lorenzon, Gloria Santoro, Annamaria Agnes, Antonio Laurino, Roberto Persiani, Domenico D'Ugo
    European Journal of Surgical Oncology.2023; 49(11): 106969.     CrossRef
  • Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study
    Chongyuan Sun, Penghui Niu, Xiaojie Zhang, Lulu Zhao, Wanqing Wang, Xiaoyi Luan, Xue Han, Yingtai Chen, Dongbing Zhao
    BMC Cancer.2023;[Epub]     CrossRef
  • Sintilimab Plus Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer and Biomarker Exploration
    Jiangpeng Wei, Xin Guo, Xisheng Yang, Jinqiang Liu, Qianqian Duan, Yuan Tan, Qin Zhang, Tingting Sun, Chuang Qi, Xiaohua Li, Gang Ji
    Future Oncology.2023; 19(36): 2395.     CrossRef
  • Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy
    Yong Chen, Fei Yuan, Lingyun Wang, Elsie Li, Zhihan Xu, Michael Wels, Weiwu Yao, Huan Zhang
    European Journal of Surgical Oncology.2022; 48(2): 339.     CrossRef
  • MORBIDITY AND SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN GASTRIC CANCER: A STUDY USING THE BECKER’S CLASSIFICATION AND REGRESSION
    Maria Cecília de Aguiar MACHADO, José Pedro Coimbra de Vargas Lobarinhas BARBOSA, Filipa Ferreira de OLIVEIRA, José Adelino Lobarinhas BARBOSA
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2022;[Epub]     CrossRef
  • Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trial
    Luca Saragoni, Leonardo Solaini, Daniele Marrelli, Maria Raffaella Ambrosio, Maria Bencivenga, Anna Tomezzoli, Carlo Milandri, Valentina Terrinazzi, Gian Luca Baiocchi, Carla Baronchelli, Flavia Foca, Giorgio Ercolani, Paolo Morgagni
    International Journal of Surgery.2021; 94: 106112.     CrossRef
  • Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy
    Zi-Ning Liu, Yin-Kui Wang, Li Zhang, Yong-Ning Jia, Shan Fei, Xiang-Ji Ying, Yan Zhang, Shuang-Xi Li, Yu Sun, Zi-Yu Li, Jia-Fu Ji
    World Journal of Gastrointestinal Oncology.2021; 13(12): 2161.     CrossRef
  • 6,837 View
  • 146 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project
Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim
Cancer Res Treat. 2021;53(1):123-130.   Published online August 18, 2020
DOI: https://doi.org/10.4143/crt.2020.559
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Next-generation sequencing (NGS) can facilitate precision medicine approaches in metastatic colorectal cancer (mCRC) patients. We investigated the molecular profiling of Korean mCRC patients under the K-MASTER project which was initiated in June 2017 as a nationwide precision medicine oncology clinical trial platform which used NGS assay to screen actionable mutations.
Materials and Methods
As of 22 January 2020, total of 994 mCRC patients were registered in K-MASTER project. Targeted sequencing was performed using three platforms which were composed of the K-MASTER cancer panel v1.1 and the SNUH FIRST Cancer Panel v3.01. If tumor tissue was not available, cell-free DNA was extracted and the targeted sequencing was performed by Axen Cancer Panel as a liquid biopsy.
Results
In 994 mCRC patients, we found 1,564 clinically meaningful pathogenic variants which mutated in 71 genes. Anti-EGFR therapy candidates were 467 patients (47.0%) and BRAF V600E mutation (n=47, 4.7%), deficient mismatch repair/microsatellite instability–high (n=15, 1.5%), HER2 amplifications (n=10, 1.0%) could be incorporated with recently approved drugs. The patients with high tumor mutation burden (n=101, 12.7%) and DNA damaging response and repair defect pathway alteration (n=42, 4.2%) could be enrolled clinical trials with immune checkpoint inhibitors. There were more colorectal cancer molecular alterations such as PIK3CA, KRAS G12C, atypical BRAF, and HER2 mutations and even rarer but actionable genes that approved or ongoing clinical trials in other solid tumors.
Conclusion
K-MASTER project provides an intriguing background to investigate new clinical trials with biomarkers and give therapeutic opportunity for mCRC patients.

Citations

Citations to this article as recorded by  
  • Tumor mutational burden in colorectal cancer: Implications for treatment
    Adriana Marques, Patrícia Cavaco, Carla Torre, Bruno Sepodes, João Rocha
    Critical Reviews in Oncology/Hematology.2024; 197: 104342.     CrossRef
  • Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer
    Yonghwa Choi, Jangwoo Lee, Keewon Shin, Ji Won Lee, Ju Won Kim, Soohyeon Lee, Yoon Ji Choi, Kyong Hwa Park, Jwa Hoon Kim
    BMC Cancer.2024;[Epub]     CrossRef
  • PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
    Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
    Cancer Research and Treatment.2023; 55(2): 531.     CrossRef
  • Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
    Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
    Scientific Reports.2023;[Epub]     CrossRef
  • Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
    Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Se
    Cancer Research and Treatment.2022; 54(1): 30.     CrossRef
  • Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan
    Saleema Mehboob Ali, Yumna Adnan, Zubair Ahmad, Hasnain Ahmed Farooqui, Tabish Chawla, S. M. Adnan Ali
    Molecular Biology Reports.2022; 49(2): 1341.     CrossRef
  • Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
    Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se
    Cancer Research and Treatment.2022; 54(1): 1.     CrossRef
  • Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
    Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won L
    The Breast.2022; 65: 172.     CrossRef
  • The importance of precision medicine in modern molecular oncology
    Yuanli Wang, Dawu Zheng
    Clinical Genetics.2021; 100(3): 248.     CrossRef
  • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
    BMB Reports.2021; 54(7): 386.     CrossRef
  • Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer
    Aitor Rodríguez-Casanova, Aida Bao-Caamano, Ramón M. Lago-Lestón, Elena Brozos-Vázquez, Nicolás Costa-Fraga, Isabel Ferreirós-Vidal, Ihab Abdulkader, Yolanda Vidal-Insua, Francisca Vázquez Rivera, Sonia Candamio Folgar, Rafael López-López, Laura Muinelo-R
    Journal of Clinical Medicine.2021; 10(19): 4487.     CrossRef
  • Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
    Saikat Chowdhury, Matan Hofree, Kangyu Lin, Dipen Maru, Scott Kopetz, John Paul Shen
    Cancers.2021; 13(19): 4923.     CrossRef
  • 9,938 View
  • 357 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer
Lin Fang, Fei-Hu Yan, Chao Liu, Jing Chen, Dan Wang, Chun-Hui Zhang, Chang-Jie Lou, Jie Lian, Yang Yao, Bo-Jun Wang, Rui-Yang Li, Shu-Ling Han, Yi-Bing Bai, Jia-Ni Yang, Zhi-Wei Li, Yan-Qiao Zhang
Cancer Res Treat. 2021;53(1):131-139.   Published online August 24, 2020
DOI: https://doi.org/10.4143/crt.2020.330
AbstractAbstract PDFSupplementary MaterialPubReader
Purpose
Systemic inflammatory response is a critical factor that promotes the initiation and metastasis of malignancies including pancreatic cancer (PC). This study was designed to determine and compare the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and fibrinogen-to-albumin ratio (FAR) in resectable PC and locally advanced or metastatic PC.
Materials and Methods
Three hundred fifty-three patients with resectable PC and 807 patients with locally advan-ced or metastatic PC were recruited in this study. These patients were classified into a training set (n=758) and a validation set (n=402). Kaplan-Meier survival plots and Cox proportional hazards regression models were used to analyze prognosis.
Results
Overall survival (OS) was significantly better for patients with resectable PC with low preoperative PLR (p=0.048) and MLR (p=0.027). Low FAR, MLR, NLR (p < 0.001), and PLR (p=0.003) were significantly associated with decreased risk of death for locally advanced or metastatic PC patients. FAR (hazard ratio [HR], 1.522; 95% confidential interval [CI], 1.261 to 1.837; p < 0.001) and MLR (HR, 1.248; 95% CI, 1.017 to 1.532; p=0.034) were independent prognostic factors for locally advanced or metastatic PC.
Conclusion
The prognostic roles of FAR, MLR, NLR, and PLR in resectable PC and locally advanced or metastatic PC were different. FAR showed the most prognostic power in locally advanced or metastatic PC. Low FAR was positively correlated with OS in locally advanced or metastatic PC, which could be used to predict the prognosis.

Citations

Citations to this article as recorded by  
  • Prognostic value of preoperative white blood cell to hemoglobin ratio and fibrinogen to albumin ratio in patients with colorectal cancer
    Kang Li, Jing Yan, Haifeng Zhang, Chunlei Lu, Weijia Wang, Mingxiao Guo, Xiaoming Zhang, Zhaoyong Zhang
    Medicine.2024; 103(3): e37031.     CrossRef
  • Prognostic value of the fibrinogen-to-albumin ratio (FAR) in patients with chronic heart failure across the different ejection fraction spectrum
    Sirui Yang, Jiangyuan Pi, Wenfang Ma, Wenyi Gu, Hongxing Zhang, Anyu Xu, Yanqing Liu, Tao Shi, Fazhi Yang, Lixing Chen
    Libyan Journal of Medicine.2024;[Epub]     CrossRef
  • Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), and Eosinophil-to-Lymphocyte Ratio (ELR) as Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
    Qian-Qian Liao, Yan-Ju Mo, Ke-Wei Zhu, Feng Gao, Bin Huang, Peng Chen, Feng-Tian Jing, Xuan Jiang, Hong-Zhen Xu, Yan-Feng Tang, Li-Wei Chu, Hai-Ling Huang, Wen-Li Wang, Fang-Ning Wei, Dan-Dan Huang, Bin-Jing Zhao, Jia Chen, Hao Zhang
    International Journal of Chronic Obstructive Pulmonary Disease.2024; Volume 19: 501.     CrossRef
  • Nomogram for Predicting Postoperative Pulmonary Metastasis in Hepatocellular Carcinoma Based on Inflammatory Markers
    Huanjie Zhou, Haiping Zheng, Ying Wang, Ming Lao, Hong Shu, Meifang Huang, Chao Ou
    Cancer Control.2024;[Epub]     CrossRef
  • Predictive value of serum albumin levels on cancer survival: a prospective cohort study
    Quan Tang, Xu Li, Chun-Rong Sun
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer
    Jing-Yao Ren, Da Wang, Li-Hui Zhu, Shuo Liu, Miao Yu, Hui Cai
    World Journal of Gastrointestinal Oncology.2024; 16(3): 732.     CrossRef
  • A High Fibrinogen-to-Albumin Ratio on Admission is Associated with Early Neurological Deterioration Following Intravenous Thrombolysis in Patients with Acute Ischemic Stroke
    Shifu Sun, Yongqing Cheng, Lei Li, Honghong Zhu, Changxia Liu, Yongjun Cao
    Journal of Inflammation Research.2024; Volume 17: 4151.     CrossRef
  • Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
    Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
    Cancer Medicine.2024;[Epub]     CrossRef
  • The prognostic role of lymphocyte-to-monocyte ratio in patients with resectable pancreatic cancer: a systematic review and meta-analysis
    Haipeng Li, Shang Peng, Ran An, Nana Du, Huan Wu, Xiangcheng Zhen, Yuanzhi Gao, Zhenghong Li, Jingting Min
    PeerJ.2024; 12: e17585.     CrossRef
  • Monocyte to high-density lipoprotein ratio based prognostic nomogram for patients following allogeneic vascular replacement pancreaticoduodenectomy
    Xiao-Wen Ye, Zu-Yu Wang, Yun-Xia Shao, Ying-Chun Tang, Xiong-Jun Dong, Ya-Ning Zhu
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer
    Lu Zhang, Yan-Ping Chen, Min Ji, Le-Qian Ying, Chun-Chun Huang, Jing-Yi Zhou, Lin Liu
    World Journal of Gastrointestinal Oncology.2024; 16(9): 3875.     CrossRef
  • Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection
    Shaofei Chang, Yiping Zou, Jing Huang, Zhifei Li, Yuexiang Liang, Song Gao
    World Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma
    Shuai Xu, Xiu-Ping Zhang, Guo-Dong Zhao, Wen-Bo Zou, Zhi-Ming Zhao, Qu Liu, Ming-Gen Hu, Rong Liu
    Hepatobiliary & Pancreatic Diseases International.2023; 22(2): 160.     CrossRef
  • Association between fibrinogen-to-albumin ratio and hemorrhagic transformation after intravenous thrombolysis in ischemic stroke patients
    Miaomiao Yang, Lisha Tang, Shijia Bing, Xiangqi Tang
    Neurological Sciences.2023; 44(4): 1281.     CrossRef
  • Predictive impact of fibrinogen-to-albumin ratio (FAR) for left ventricular dysfunction in acute coronary syndrome: a cross-sectional study
    Xuan Wang, Yi Hu, Hao Luan, Chaodi Luo, Kamila·Kamili, Tingting Zheng, Gang Tian
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Fibrinogen-to-albumin ratio percentage: An independent predictor of disease severity and prognosis in anti-N-methyl-D-aspartate receptor encephalitis
    Juan Du, Yingzhe Shao, Yajun Song, Kaixin Wang, Xuan Yang, Yanfei Li, Yaobing Yao, Zhe Gong, Yanjie Jia
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer
    Yuanlong Gu, Qianjin Hua, Zhipeng Li, Xingli Zhang, Changjie Lou, Yangfen Zhang, Wei Wang, Peiyuan Cai, Juan Zhao
    BMC Cancer.2023;[Epub]     CrossRef
  • Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysis
    Junyan Kou, Jing Huang, Jun Li, Zhen Wu, Liwei Ni
    Clinical and Experimental Medicine.2023; 23(7): 3895.     CrossRef
  • Prognostic analysis of the plasma fibrinogen combined with neutrophil‐to‐lymphocyte ratio in patients with non–small cell lung cancer after radical resection
    Gao‐Xiang Wang, Zhi‐Ning Huang, Ying‐Quan Ye, Shan‐Ming Tao, Mei‐Qing Xu, Mei Zhang, Ming‐Ran Xie
    Thoracic Cancer.2023; 14(15): 1383.     CrossRef
  • Clinical features of patients with MOG-IgG associated disorders and analysis of the relationship between fibrinogen-to-albumin ratio and the severity at disease onset
    Yue Li, Sai Wang, Panpan Liu, Jinxiu Ma, Xinjing Liu, Jing Yuan
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Low albumin‐to‐fibrinogen ratio predicts adverse clinical outcomes after primary total joint arthroplasty: A retrospective observational investigation
    Jingjing Shang, Shijie Jiang, Jinhong Gong, Gongyin Zhao, Dan Su, Liangliang Wang
    International Wound Journal.2023; 20(9): 3690.     CrossRef
  • The modified lymphocyte C-reactive protein score is a promising indicator for predicting 3-year mortality in elderly patients with intertrochanteric fractures
    Zile He, Chuangxin Zhang, Mingzi Ran, Xin Deng, Zilin Wang, Yanhong Liu, Hao Li, Jingsheng Lou, Weidong Mi, Jiangbei Cao
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection
    Yu-Ting Jiang, Tian-Cheng Wang, Wei Zhang
    Journal of Inflammation Research.2023; Volume 16: 3479.     CrossRef
  • Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status
    Zhengfeng Zhang, Dazhen Wang, Jianji Zhang, Yuli Ruan, Lu Zhao, Liu Yang, Ze Liu, Lei Yang, Changjie Lou
    Cancer Immunology, Immunotherapy.2023; 72(11): 3635.     CrossRef
  • The predictive value of the preoperative albumin‐to‐fibrinogen ratio for postoperative hospital length of stay in liver cancer patients
    Fang Li, Yuetong Ren, Jiacheng Fan, Jin Zhou
    Cancer Medicine.2023; 12(20): 20321.     CrossRef
  • Inflammatory Markers Showed Significant Incremental Value for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients
    Xiao Wang, Wenjun Wang, Xixiang Lin, Xu Chen, Mingxiang Zhu, Hongli Xu, Kunlun He
    Life.2023; 13(10): 1990.     CrossRef
  • FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis
    Jili Xu, Hongmei Zhang, Nan Che, Hengjin Wang
    Clinical and Experimental Medicine.2023; 23(8): 4779.     CrossRef
  • Development and validation of a prognostic nomogram model incorporating routine laboratory biomarkers for preoperative patients with endometrial cancer
    Rong Cong, Mingyang Li, Wan Xu, Xiaoxin Ma, Shuhe Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer
    Liuqing Ye, Guoming Zhou, Lingling Zhou, Dongguo Wang, Shunqiang Xiong, Chibo Liu, Guobing Zhang
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma
    Koji Kubota, Akira Shimizu, Yuji Soejima
    Annals of Surgical Oncology.2022; 29(2): 1449.     CrossRef
  • Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma
    Koji Kubota, Akira Shimizu, Tsuyoshi Notake, Hitoshi Masuo, Kiyotaka Hosoda, Koya Yasukawa, Hikaru Hayashi, Kentaro Umemura, Atsushi Kamachi, Takamune Goto, Hidenori Tomida, Shiori Yamazaki, Yuji Soejima
    Annals of Surgical Oncology.2022; 29(2): 1437.     CrossRef
  • Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting
    Nardeen Perko, Shaker A. Mousa
    Cancers.2022; 14(12): 2879.     CrossRef
  • A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study
    Xiu-Ping Zhang, Yuan-Xing Gao, Shuai Xu, Guo-Dong Zhao, Ming-Gen Hu, Xiang-Long Tan, Zhi-Ming Zhao, Rong Liu
    International Journal of Surgery.2022; 106: 106891.     CrossRef
  • Predictive Value of Fibrinogen to Albumin Ratio for the Multivessel-Coronary Chronic Total Occlusion
    婷 于
    Advances in Clinical Medicine.2022; 12(09): 8311.     CrossRef
  • Preoperative peripheral blood inflammatory markers especially the fibrinogen-to-lymphocyte ratio and novel FLR-N score predict the prognosis of patients with early-stage resectable extrahepatic cholangiocarcinoma
    Shijie Li, Xingli Zhang, Changjie Lou, Yuanlong Gu, Juan Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Fibrinogen-to-Albumin Ratio Predicts Postcontrast Acute Kidney Injury in Patients with Non-ST Elevation Acute Coronary Syndrome after Implantation of Drug-Eluting Stents
    Yong Qiao, Mingkang Li, Linqing Li, Chengchun Tang, Vijaya Anand
    Journal of the Renin-Angiotensin-Aldosterone System.2022;[Epub]     CrossRef
  • Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
    Xiuqiong Chen, Zhaona Li, Jing Zhou, Qianhui Wei, Xinyue Wang, Richeng Jiang
    PeerJ.2022; 10: e14566.     CrossRef
  • Diagnostic and Prognostic Value of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratios on Acute Pancreatitis Patients
    Hasan ERGENÇ, Zeynep ERTÜRK, Ahmet Tarık EMİNLER, Hakan CİNEMRE
    Online Türk Sağlık Bilimleri Dergisi.2022; 7(1): 80.     CrossRef
  • Prognostic value of albumin-fibrinogen ratio in subarachnoid hemorrhage patients
    Xuyang Liu, Zhiyuan Yu, Dingke Wen, Lu Ma, Chao You
    Medicine.2021; 100(17): e25764.     CrossRef
  • Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study
    Huayang Pang, Weihan Zhang, Xianwen Liang, Ziqi Zhang, Xiaolong Chen, Linyong Zhao, Kai Liu, Danil Galiullin, Kun Yang, Xinzu Chen, Jiankun Hu
    Advances in Therapy.2021; 38(9): 4917.     CrossRef
  • Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection
    Li-Peng Zhang, Hu Ren, Yong-Xing Du, Cheng-Feng Wang
    World Journal of Gastroenterology.2020; 26(46): 7382.     CrossRef
  • 9,310 View
  • 199 Download
  • 43 Web of Science
  • 41 Crossref
Close layer
Adherence to the Recommended Intake of Calcium and Colorectal Cancer Risk in the HEXA Study
Jeeyoo Lee, Aesun Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee
Cancer Res Treat. 2021;53(1):140-147.   Published online August 25, 2020
DOI: https://doi.org/10.4143/crt.2020.480
AbstractAbstract PDFPubReaderePub
Purpose
Dietary calcium intake has been suggested to be protective against the development of colorectal cancer. The mean dietary calcium intake of Koreans is 490 mg/day, which is far below the recommended calcium intake of 700-800 mg/day. In this study, we explored the relationship between dietary calcium intake and colorectal cancer development in Koreans with relatively low calcium intake compared with individuals in Western countries.
Materials and Methods
The Health Examinees Study, a large-scale genomic community-based prospective cohort study, was designed to identify the general characteristics of major chronic diseases in Koreans. A total of 119,501 participants aged 40-69 years recruited between 2004 and 2013 were included in this analysis. The calcium intake level was categorized using the Dietary Reference Intakes for Koreans (KDRIs). The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and the corresponding 95% confidence intervals (CIs) for colorectal cancer risk, adjusting for potential confounders.
Results
In the multivariable-adjusted model, compared with the group that consumed less than the recommended amount of calcium, the group that consumed more than the recommended intake of calcium showed a significant reduction in the risk of colorectal cancer in women. (HR, 0.54; 95% CI, 0.31 to 0.95). Among men, however, no significant association was observed between dietary calcium intake and colorectal cancer risk (HR, 0.89; 95% CI, 0.54 to 1.45).
Conclusion
Korean women who adhere to the recommended intake of calcium showed a reduced risk of colorectal cancer.

Citations

Citations to this article as recorded by  
  • Implication of calcium supplementations in health and diseases with special focus on colorectal cancer
    Shahanavaj Khan, S. Needa Mosvi, Saeed Vohra, Nitesh Kumar Poddar
    Critical Reviews in Clinical Laboratory Sciences.2024; 61(6): 496.     CrossRef
  • The burden of colorectal cancer attributable to dietary risk in Middle East and North African from 1990 to 2019
    Yahya Pasdar, Fatemeh Khosravi Shadmani, Hawal Lateef Fateh, Davood Soleimani, Behrooz Hamzeh, Mojtaba Ghalandari, Behrooz Moloudpour, Mitra Darbandi
    Scientific Reports.2023;[Epub]     CrossRef
  • Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies
    Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim
    Epidemiology and Health.2023; 45: e2023102.     CrossRef
  • Anti-colorectal cancer effects of seaweed-derived bioactive compounds
    Yunhua Fu, Dong Xie, Yinghao Zhu, Xinyue Zhang, Hao Yue, Kai Zhu, Zifeng Pi, Yulin Dai
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Osteosarcopenic adiposity syndrome update and the role of associated minerals and vitamins
    Jasminka Z. Ilich
    Proceedings of the Nutrition Society.2021; 80(3): 344.     CrossRef
  • 6,325 View
  • 150 Download
  • 5 Crossref
Close layer
An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer
Jiahui Chen, Anqiang Wang, Jun Ji, Kai Zhou, Zhaode Bu, Guoqing Lyu, Jiafu Ji
Cancer Res Treat. 2021;53(1):148-161.   Published online August 31, 2020
DOI: https://doi.org/10.4143/crt.2020.424
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Gastric cancer (GC) has substantial biological differences between Asian and non-Asian populations, which makes it difficult to have a unified predictive measure for all people. We aimed to identify novel prognostic biomarkers to help predict the prognosis of Asian GC patients.
Materials and Methods
We investigated the differential gene expression between GC and normal tissues of GSE66229. Univariate, multivariate and Lasso Cox regression analyses were conducted to establish a four-gene-related prognostic model based on the risk score. The risk score was based on a linear combination of the expression levels of individual genes multiplied by their multivariate Cox regression coefficients. Validation of the prognostic model was conducted using The Cancer Genome Atlas (TCGA) database. A nomogram containing clinical characteristics and the prognostic model was established to predict the prognosis of Asian GC patients.
Results
Four genes (RBPMS2, RGN, PLEKHS1, and CT83) were selected to establish the prognostic model, and it was validated in the TCGA Asian cohort. Receiver operating characteristic analysis confirmed the sensitivity and specificity of the prognostic model. Based on the prognostic model, a nomogram containing clinical characteristics and the prognostic model was established, and Harrell’s concordance index of the nomogram for evaluating the overall survival significantly higher than the model only focuses on the pathologic stage (0.74 vs. 0.64, p < 0.001).
Conclusion
The four-gene-related prognostic model and the nomogram based on it are reliable tools for predicting the overall survival of Asian GC patients.

Citations

Citations to this article as recorded by  
  • Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
    Jing Wu, Shilong Zhang, Shan Yu, Guo An, Yi Wang, Yiyi Yu, Li Liang, Yan Wang, Xiaojing Xu, YanShi Xiong, Di Shao, Zhun Shi, Nannan Li, Jingyuan Wang, Dawei Jin, Tianshu Liu, Yuehong Cui
    Nature Communications.2024;[Epub]     CrossRef
  • An integrated analysis of prognostic mRNA signature in early- and progressive-stage gastric adenocarcinoma
    Xiaoling Hong, Kai Zhuang, Na Xu, Jiang Wang, Yong Liu, Siqi Tang, Junzhang Zhao, Zunnan Huang
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • Analysis and application of RNA binding protein gene pairs to predict the prognosis of gastric cancer
    Zhi-kun Ning, Hua-kai Tian, Jiang Liu, Ce-gui Hu, Zi-tao Liu, Hui Li, Zhen Zong
    Heliyon.2023; 9(7): e18242.     CrossRef
  • PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
    Tamara A.M. Chessa, Piotr Jung, Arqum Anwar, Sabine Suire, Karen E. Anderson, David Barneda, Anna Kielkowska, Barzan A. Sadiq, Ieng Wai Lai, Sergio Felisbino, Daniel J. Turnham, Helen B. Pearson, Wayne A. Phillips, Junko Sasaki, Takehiko Sasaki, David Oxl
    Molecular Cell.2023; 83(16): 2991.     CrossRef
  • Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma
    Dun Pan, Hui Chen, Jiaxiang Xu, Xin Lin, Liangqing Li
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Bayesian hierarchical lasso Cox model: A 9-gene prognostic signature for overall survival in gastric cancer in an Asian population
    Jiadong Chu, Na Sun, Wei Hu, Xuanli Chen, Nengjun Yi, Yueping Shen, Andy T. Y. Lau
    PLOS ONE.2022; 17(4): e0266805.     CrossRef
  • Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
    Ya Guo, Yin Bin Zhang, Yi Li, Wang Hui Su, Shan He, Shu Pei Pan, Kun Xu, Wei Hua Kou, Luca Falzone
    International Journal of Genomics.2022; 2022: 1.     CrossRef
  • KK-LC-1 may be an effective prognostic biomarker for gastric cancer
    Jun Ji, Jiahui Chen, Anqiang Wang, Wei Zhang, Hongge Ju, Yang Liu, Leping Li
    BMC Cancer.2021;[Epub]     CrossRef
  • Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer
    Chen Chen, Dan Gao, Jinlong Huo, Rui Qu, Youming Guo, Xiaochi Hu, Libo Luo
    Scientific Reports.2021;[Epub]     CrossRef
  • Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer
    Siwei Pan, Qi Gao, Qingchuan Chen, Pengfei Liu, Yuen Tan, Funan Liu, Huimian Xu
    International Immunopharmacology.2021; 101: 108258.     CrossRef
  • 8,538 View
  • 180 Download
  • 12 Web of Science
  • 10 Crossref
Close layer
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
Hyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, Danbee Kim, Sunmin Lee, Jaehoon Shin, Seung-Mo Hong, Ki-Hun Kim, Dong‐Hwan Jung, Gi‐Won Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Baek-Yeol Ryoo, Jae Ho Jeong, Kyu-pyo Kim, Sang-Yeob Kim, Changhoon Yoo
Cancer Res Treat. 2021;53(1):162-171.   Published online August 31, 2020
DOI: https://doi.org/10.4143/crt.2020.704
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.
Materials and Methods
A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.
Results
The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.
Conclusion
The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.

Citations

Citations to this article as recorded by  
  • Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
    Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, Shuai Yang, Ruizhi Wang, Ge Zhang, Zhengrui Li, Run Shi, Zhan Wang, Qiong Lu
    Molecular Cancer.2024;[Epub]     CrossRef
  • Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma
    Sijia Hua, Xinyi Gu, Hangbin Jin, Xiaofeng Zhang, Qiang Liu, Jianfeng Yang
    Biomedicine & Pharmacotherapy.2024; 177: 117080.     CrossRef
  • Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
    Luohang Ni, Jianing Xu, Quanpeng Li, Xianxiu Ge, Fei Wang, Xueting Deng, Lin Miao
    Cancer Management and Research.2024; Volume 16: 941.     CrossRef
  • Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
    Yeong Hak Bang, Choong-kun Lee, Kyunghye Bang, Hyung-Don Kim, Kyu-pyo Kim, Jae Ho Jeong, Inkeun Park, Baek-Yeol Ryoo, Dong Ki Lee, Hye Jin Choi, Taek Chung, Seung Hyuck Jeon, Eui-Cheol Shin, Chiyoon Oum, Seulki Kim, Yoojoo Lim, Gahee Park, Chang Ho Ahn, T
    Clinical Cancer Research.2024; 30(20): 4635.     CrossRef
  • Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma
    S.-Y. Jun, S. An, S.-M. Hong, J.-Y. Kim, K.-P. Kim
    ESMO Open.2024; 9(11): 103969.     CrossRef
  • Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
    Siqi Yang, Ruiqi Zou, Yushi Dai, Yafei Hu, Fuyu Li, Haijie Hu
    International Journal of Oncology.2023;[Epub]     CrossRef
  • Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
    Chaoqun Li, Lei Bie, Muhua Chen, Jieer Ying
    Exploration of Targeted Anti-tumor Therapy.2023; 4(6): 1310.     CrossRef
  • Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment
    Hyung-Don Kim, Sun Young Kim, Jihun Kim, Jeong Eun Kim, Yong Sang Hong, Buhm Han, Eunyoung Tak, Yeon-Mi Ryu, Sang-Yeob Kim, Tae Won Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
    Taek Chung, Young Nyun Park
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
    Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch
    Journal of Experimental & Clinical Cancer Research.2022;[Epub]     CrossRef
  • Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Jwa Hoon Kim, Gi Hwan Kim, Yeon-Mi Ryu, Sang-Yeob Kim, Hyung-Don Kim, Shin Kyo Yoon, Yong Mee Cho, Jae Lyun Lee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
    Tong Fu, Lei-Jie Dai, Song-Yang Wu, Yi Xiao, Ding Ma, Yi-Zhou Jiang, Zhi-Ming Shao
    Journal of Hematology & Oncology.2021;[Epub]     CrossRef
  • 7,721 View
  • 230 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
Yingjia Wu, Jinbin Chen, Lei Zhao, Qiaoqiao Li, Jinhan Zhu, Hong Yang, Suping Guo, Mian Xi
Cancer Res Treat. 2021;53(1):172-183.   Published online September 4, 2020
DOI: https://doi.org/10.4143/crt.2020.594
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop a nomogram for predicting pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) by integrating hematological biomarkers and clinicopathological characteristics.
Materials and Methods
Between 2003 and 2017, 306 ESCC patients who underwent neoadjuvant CRT followed by esophagectomy were analyzed. Besides clinicopathological factors, hematological parameters before, during, and after CRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and internally validated.
Results
Absolute lymphocyte count (ALC), lymphocyte to monocyte ratio, albumin, hemoglobin, white blood cell, neutrophil, and platelet count generally declined, whereas neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) increased significantly following neoadjuvant CRT. After surgery, 124 patients (40.5%) achieved a pCR. The pCR group demonstrated significantly more favorable survival than the non-pCR group. On multivariate analysis, significant factors associated with pCR included sex, chemotherapy regimen, post-CRT endoscopic finding, pre-CRT NLR, ALC nadir during CRT, and post-CRT PLR, which were incorporated into the prediction model. The nomogram indicated good accuracy in predicting pCR, with a C-index of 0.75 (95% confidence interval, 0.71 to 0.78).
Conclusion
Female, chemotherapy regimen of cisplatin/vinorelbine, negative post-CRT endoscopic finding, pre-CRT NLR (≤ 2.1), ALC nadir during CRT (> 0.35 ×109/L), and post-CRT PLR (≤ 83.0) were significantly associated with pCR in ESCC patients treated with neoadjuvant CRT. A nomogram incorporating hematological biomarkers to predict pCR was developed and internally validated, showing good predictive performance.

Citations

Citations to this article as recorded by  
  • CT-based deep learning radiomics and hematological biomarkers in the assessment of pathological complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma: A two-center study
    Meng Zhang, Yukun Lu, Hongfu Sun, Chuanke Hou, Zichun Zhou, Xiao Liu, Qichao Zhou, Zhenjiang Li, Yong Yin
    Translational Oncology.2024; 39: 101804.     CrossRef
  • A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors
    Wei-Xiang Qi, Shuyan Li, Jifeng Xiao, Huan Li, Jiayi Chen, Shengguang Zhao
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Ting Qian, Delin Liu, Guochun Cao, Zhipeng Chen, Qin Zhang
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Guihong Liu, Tao Chen, Xin Zhang, Binbin Hu, Jiayun Yu
    Cancer Medicine.2024;[Epub]     CrossRef
  • Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis
    Xing Gao, Hidde C G Overtoom, Ben M Eyck, Shi-Han Huang, Daan Nieboer, Pieter C van der Sluis, Sjoerd M Lagarde, Bas P L Wijnhoven, Yin-Kai Chao, Jan J B van Lanschot
    British Journal of Surgery.2024;[Epub]     CrossRef
  • Integrating MR radiomics and dynamic hematological factors predicts pathological response to neoadjuvant chemoradiotherapy in esophageal cancer
    Yunsong Liu, Zeliang Ma, Yongxing Bao, Xin Wang, Yu Men, Xujie Sun, Feng Ye, Kuo Men, Jianjun Qin, Nan Bi, Liyan Xue, Zhouguang Hui
    Heliyon.2024; 10(13): e33702.     CrossRef
  • Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy
    Chien-Ming Lo, Hung-I. Lu, Yu-Ming Wang, Yen-Hao Chen, Yu Chen, Li-Chun Chen, Shau-Hsuan Li
    Perioperative Medicine.2024;[Epub]     CrossRef
  • Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery
    Ji Yong Kim, Jea Kwang Yun, Yong-Hee Kim, Seung-il Park, Jeong Hoon Lee, Hwoon-Yong Jung, Gin Hyug Lee, Ho June Song, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Sung-Bae Kim, Kyung-Ja Cho, Jin-Sook Ryu, Jong Hoon Kim, Jihoon Kang, Sook Ryun Park, Hyeong Ryul
    Annals of Surgical Oncology.2024; 31(10): 6662.     CrossRef
  • The relationship between systemic immune-inflammation indexes and treatment response in locally advanced esophageal cancer
    Esra KEKİLLİ, Ebru ATASEVER AKKAŞ, Serab UYAR, Emre YEKEDÜZ
    Anatolian Current Medical Journal.2023; 5(1): 53.     CrossRef
  • A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Yalan Yang, Dao Xin, Huike Wang, Lulu Guan, Xiangrui Meng, Taiying Lu, Xiwen Bai, Feng Wang
    Journal of Inflammation Research.2023; Volume 16: 1443.     CrossRef
  • Gut microbiome can predict chemoradiotherapy efficacy in patients with esophageal squamous cell carcinoma
    Takuma Sasaki, Yasunori Matsumoto, Kentaro Murakami, Satoshi Endo, Takeshi Toyozumi, Ryota Otsuka, Kazuya Kinoshita, Jie Hu, Shinichiro Iida, Hiroki Morishita, Yuri Nishioka, Akira Nakano, Masaya Uesato, Hisahiro Matsubara
    Esophagus.2023; 20(4): 691.     CrossRef
  • Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
    Wei‐Xiang Qi, Xiaoyan Wang, Chengqiang Li, Shuyan Li, Huan Li, Feifei Xu, Jiayi Chen, Shengguang Zhao, Hecheng Li
    Thoracic Cancer.2023; 14(17): 1556.     CrossRef
  • Prognostic analysis and treatment utilization of different treatment strategies in elderly esophageal cancer patients with distant metastases: a SEER database analysis
    Lian-Qiang Han, Ting-Ting Cui, Nian-Jun Xiao, Wen Li
    Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15413.     CrossRef
  • Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy
    Dan He, Shulan Du, Songyuan He, Hao Song, Bo Pu, Guojun Zhang, Chuan Yang
    Medicine.2023; 102(49): e36554.     CrossRef
  • Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Young Seob Shin, Jeong Yun Jang, Ye Jin Yoo, Jesang Yu, Kye Jin Song, Yoon Young Jo, Sung-Bae Kim, Sook Ryun Park, Ho June Song, Yong-Hee Kim, Hyeong Ryul Kim, Jong Hoon Kim
    Gastroenterology Report.2023;[Epub]     CrossRef
  • Impact of Platelets to Lymphocytes Ratio and Lymphocytes during Radical Concurrent Radiotherapy and Chemotherapy on Patients with Nonmetastatic Esophageal Squamous Cell Carcinoma
    Yaotian Zhang, Ning Han, Xue Zeng, Chaonan Sun, Shichen Sun, Xinchi Ma, Yanyu Zhang, Zhuang Liu, Zilan Qin, Hong Guo, Yubing Li, Na Zhang, Bruno Vincenzi
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis
    Liubing Hu, Jiyue Liu, Hideaki Shimada, Masaaki Ito, Kazuo Sugimoto, Takaki Hiwasa, Qinghua Zhou, Jianshuang Li, Si Shen, Hao Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma
    Noel E Donlon, Maria Davern, Fiona O’Connell, Andrew Sheppard, Aisling Heeran, Anshul Bhardwaj, Christine Butler, Ravi Narayanasamy, Claire Donohoe, James J Phelan, Niamh Lynam-Lennon, Margaret R Dunne, Stephen Maher, Jacintha O’Sullivan, John V Reynolds,
    World Journal of Gastroenterology.2022; 28(21): 2302.     CrossRef
  • Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
    Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen, Xiangdong Cheng
    Journal of Inflammation Research.2022; Volume 15: 3783.     CrossRef
  • The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
    Xiaoyan Sun, Yingnan Feng, Bin Zhang, Wuhao Huang, Xiaoliang Zhao, Hua Zhang, Dongsheng Yue, Changli Wang
    Cancer Research and Treatment.2022; 54(4): 1017.     CrossRef
  • The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
    Jin Zhou, Hai-Ping Lin, Xin Xu, Xiao-Hang Wang, Ling Rong, Yao Zhang, Lei Shen, Lei Xu, Wei-Ting Qin, Qing Ye, Xiu-Mei Ma, Yong-Rui Bai
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • 7,375 View
  • 183 Download
  • 23 Web of Science
  • 21 Crossref
Close layer
Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis
Yuan Zhang, Lufei Zhang, Sinan Lu, Yucheng Xiang, Cheng Zeng, Tianyu He, Yuan Ding, Weilin Wang
Cancer Res Treat. 2021;53(1):184-198.   Published online October 5, 2020
DOI: https://doi.org/10.4143/crt.2020.192
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver primary tumors but its treatments are limited. Bioinformatics showed that the expression level of long non-coding RNA cancer-associated susceptibility 15 gene (CASC15) is correlated with ICC progression, but its functional mechanism remains unclear.
Materials and Methods
Tissues from ICC patients, tumor and adjacent tissue, were used for detection of the expression of CASC15. Clinical data were also collected for clinicopathologic and survival analysis. Short interfering RNA and lentiviral short hairpin RNA were used to knock down CASC15 and PRDX2 expression in ICC cell lines, for the analysis of changes of cell function and xenografts. RNA-pulldown and RNA immunoprecipitation assays were used to detect RNA-binding protein, PRDX2. Male nude mice were used for ICC xenografts, and livers were collected after 4 weeks for immunohistochemistry.
Results
CASC15 is highly expressed in ICC tissues and is related to higher TNM stage. Knockdown of CASC15 in ICC cells reduced cell proliferation, migration, invasiveness and increased apoptosis, and G1/S block. PRDX2 bound to CASC15. Knockdown of CASC15 decreased PRDX2 expression which was rescued by the inhibition of proteasome formation. Downregulation of PRDX2 resulted in G1/S block, reduced ICC cell invasion. Downregulation of CASC15 inhibited phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway through downregulating of PRDX2 and overexpressed PRDX2 rescued the block. CASC15 knockout in ICC xenografts suppressed tumor development in vivo, decreased the expression of PRDX2 and Ki67 and inhibited PI3K/AKT pathway.
Conclusion
CASC15 promotes ICC possibly by targeting PRDX2 via the PI3K/AKT pathway, indicating poor prognosis and high degree of malignancy of ICC.

Citations

Citations to this article as recorded by  
  • Exploring the mechanism of LncRNA CASC15 affecting hepatocellular carcinoma through miRNA
    Qingshan Cai, Dongyang Wu, Yueling Shen, Shudong Li, Liyou Liu, Dong Liu, Yong Li, Xiaonan Chen, Limin Wang, Jianxing Zheng
    Medicine.2024; 103(5): e35859.     CrossRef
  • The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma
    Mete Ucdal, Ayse Burus, Basak Celtikci
    International Journal of Hepatobiliary and Pancreatic Diseases.2024; 14(2): 1.     CrossRef
  • A review on the role of ncRNAs in the pathogenesis of cholangiocarcinoma
    Soudeh Ghafouri-Fard, Arash Safarzadeh, Bashdar Mahmud Hussen, Mohammad Taheri, Majid Samsami
    International Journal of Biological Macromolecules.2023; 225: 809.     CrossRef
  • A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor
    Bin Chang, Zhe Wang, Min Ren, Qianlan Yao, Lu Zhao, Xiaoyan Zhou
    International Journal of Gynecological Pathology.2023; 42(5): 451.     CrossRef
  • Development and validation of combined Ki67 status prediction model for intrahepatic cholangiocarcinoma based on clinicoradiological features and MRI radiomics
    Xianling Qian, Changwu Zhou, Fang Wang, Xin Lu, Yunfei Zhang, Lei Chen, Mengsu Zeng
    La radiologia medica.2023; 128(3): 274.     CrossRef
  • A study of the prognostic value of long non-coding RNA CASC15 in human solid tumors utilizing The Cancer Genome Atlas (TCGA) datasets and a meta-analysis
    Weiwei Chen, Wenqi Qian, Jun Nie, Mintao Dai
    Clinical and Experimental Medicine.2022;[Epub]     CrossRef
  • Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma
    Yanhua Wu, Khizar Hayat, Yufei Hu, Jianfeng Yang
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway
    Ziyan Chen, Bangjie He, Jungang Zhao, Jiacheng Li, Yifeng Zhu, Leilei Li, Wenming Bao, Jiuyi Zheng, Haitao Yu, Gang Chen
    Phytomedicine.2022; 104: 154323.     CrossRef
  • Cystic angiomatosis in children: clinical experience and review of literature
    Wen Chao Li, Li Liu, Zhen Dong Wang, Hui Chen, Guang Liu, Zhi Chun Feng
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma
    Pei-Jian Zhang, Meng-Dong Liu, Fang-Yong Fan, Ke-Xia Liu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • LncRNA CASC15 promotes the proliferation of papillary thyroid carcinoma cells by regulating the miR-7151–5p/WNT7A axis
    Dongfang Bai, Chong Guo, Aimin Wang, Guolong Pang, Jing Gao, Chuan Wang, Dapeng Zhao, Jie Yang, Jianmin Ren
    Pathology - Research and Practice.2021; 225: 153561.     CrossRef
  • LncRNA CASC15 Promotes Cerebral Ischemia/Reperfusion Injury via miR-338-3p/ETS1 Axis in Acute Ischemic Stroke
    Chen Chen, Linjing Wang, Li Wang, Qi Liu, Chunying Wang
    International Journal of General Medicine.2021; Volume 14: 6305.     CrossRef
  • Protein profiling reveals potential isomiR-associated cross-talks among RNAs in cholangiocarcinoma
    Li Guo, Yuyang Dou, Yifei Yang, Shiqi Zhang, Yihao Kang, Lulu Shen, Lihua Tang, Yaodong Zhang, Changxian Li, Jun Wang, Tingming Liang, Xiangcheng Li
    Computational and Structural Biotechnology Journal.2021; 19: 5722.     CrossRef
  • 7,219 View
  • 178 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
Woochan Park, Ju-Hee Bang, Ah-Rong Nam, Mei Hua Jin, Hyerim Seo, Jae-Min Kim, Kyoung Seok Oh, Tae-Yong Kim, Do-Youn Oh
Cancer Res Treat. 2021;53(1):199-206.   Published online October 6, 2020
DOI: https://doi.org/10.4143/crt.2020.497
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its prognostic implication and dynamics during chemotherapy in advanced gastric cancer (GC).
Materials and Methods
We prospectively enrolled 68 GC patients who were candidates for palliative standard first-line chemotherapy, and serially collected blood at baseline and after one cycle of chemotherapy, at the best response and after disease progression. sPDL1 was measured using an enzyme-linked immunosorbent assay. Response to chemotherapy, overall survival (OS), progressionfree survival (PFS) and other prognostic factors including neutrophil-lymphocyte ratio (NLR) were obtained. The cut-off value of sPDL1 levels for survival analysis was found using C-statistics.
Results
The median baseline sPDL1 was 0.8 ng/mL (range, 0.06 to 6.06 ng/mL). The median OS and PFS were 14.9 months and 8.0 months, respectively. sPDL1 and NLR showed a weak positive correlation (Spearman’s rho=0.301, p=0.013). Patients with low levels of sPDL1 at diagnosis (< 1.92 ng/mL) showed a better OS and PFS than patients with a high sPDL1. The baseline sPDL1 before treatment was higher in the progressive disease group than in the stable disease and partial response groups. Patients whose sPDL1 increased after the first cycle of chemotherapy showed worse PFS and OS. Following disease progression, sPDL1 increased compared with the baseline.
Conclusion
sPDL1 at prechemotherapy confers a prognostic value for PFS and OS in GC patients under palliative first-line chemotherapy. Dynamics of sPDL1 during chemotherapy correlates with disease progression.

Citations

Citations to this article as recorded by  
  • Laccase-inspired bi-amino acid MOFs with high substrate affinity: Catalytic deposition induced “signal-down” electrochemical response towards PD-L1
    Ruhui Hu, Suyun Zhong, Hezhen Liu, Yawen Liu, Hongxia Chen, Xiaojun Hu
    Sensors and Actuators B: Chemical.2024; 399: 134773.     CrossRef
  • Prognostic significance of soluble PD-L1 in prostate cancer
    Margarita Zvirble, Zilvinas Survila, Paulius Bosas, Neringa Dobrovolskiene, Agata Mlynska, Gintaras Zaleskis, Jurgita Jursenaite, Dainius Characiejus, Vita Pasukoniene
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer
    Kotoe Oshima
    American Journal of Cancer Research.2024; 14(3): 1174.     CrossRef
  • Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
    Lin Chen, Yuqing Chao, Wenjing Li, Zhixia Wu, Qinchuan Wang
    Biomarker Research.2024;[Epub]     CrossRef
  • Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
    Xiao-Peng Duan, Ke Liu, Xiao-Dong Jiao, Bao-Dong Qin, Bing Li, Xi He, Yan Ling, Ying Wu, Shi-Qi Chen, Yuan-Sheng Zang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
    Kabsoo Shin, Joori Kim, Se Jun Park, Myung Ah Lee, Jae Myung Park, Myung-Gyu Choi, Donghoon Kang, Kyo Young Song, Han Hong Lee, Ho Seok Seo, Sung Hak Lee, Bohyun Kim, Okran Kim, Juyeon Park, Nahyeon Kang, In-Ho Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications
    Takahiro Shinozuka, Mitsuro Kanda, Yasuhiro Kodera
    Expert Review of Molecular Diagnostics.2023; 23(8): 701.     CrossRef
  • The predictive role of soluble programmed death ligand 1 in digestive system cancers
    Jian Ruan, Zhihong Zhao, Yuting Qian, Ruilian Xu, Guixiang Liao, Feng-Ming (Spring) Kong
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?
    Magdolna Dank, Dorottya Mühl, Magdolna Herold, Lilla Hornyák, Attila Marcell Szasz, Zoltan Herold
    Journal of Clinical Medicine.2022; 11(16): 4815.     CrossRef
  • How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
    Michele Ghidini, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco, Shelize Khakoo
    Journal of Clinical Medicine.2021; 10(7): 1412.     CrossRef
  • 6,939 View
  • 135 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Gynecologic cancer
Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation
Go Woon Jeong, Wonkyo Shin, Dong Ock Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
Cancer Res Treat. 2021;53(1):207-211.   Published online August 11, 2020
DOI: https://doi.org/10.4143/crt.2020.364
AbstractAbstract PDFPubReaderePub
Purpose
The BRCA1 or BRCA2 gene is transmitted in an autosomal dominant fashion, and genetic testing of first-degree relatives of patients with family-specific mutation (FSM) is recommended. This study examined factors affecting the uptake of FSM testing among relatives of patients with peritoneal, ovarian, or fallopian tube (POFT) cancer with confirmed BRCA1 or BRCA2 germline mutation.
Materials and Methods
Data from medical charts of 392 eligible patients and their relatives who had undergone outpatient genetic counseling/testing were retrospectively reviewed. Clinical factors were compared between family members who had and had not undergone genetic counseling/testing.
Results
The uptake of FSM testing was 30.5% (129/423) among first-degree living relatives and 53.5% (69/129) within the overall family unit. The average time from genetic testing of the proband to the first FSM test within a family was 168 days (range, 23 to 681 days). Having a living father (33.8% vs. 13.3%, p=0.007) and daughter (79.4% vs. 60.3%, p=0.019) increased the uptake of FSM testing. FSM testing was more likely among female than among male relatives of cancer patients (40.9% vs. 17.6%, p < 0.001).
Conclusion
Approximately one-third of first-degree relatives of patients with a POFT cancer with BRCA1 or BRCA2 mutation underwent FSM testing. Having a living father or daughter was a factor affecting the uptake of FSM testing, which was higher among female than among male relatives of the proband. This discrepancy might be due to a misconception that the BRCA gene is associated with women rather than with men.

Citations

Citations to this article as recorded by  
  • Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
    Lucia Trevisan, Lea Godino, Linda Battistuzzi, Giovanni Innella, Elena Luppi, Giulia Buzzatti, Viviana Gismondi, Eva Blondeaux, Luigina Ada Bonelli, Daniela Turchetti, Liliana Varesco
    Familial Cancer.2024; 23(2): 197.     CrossRef
  • Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genes
    Nihat B. Agaoglu, Brittany L. Bychkovsky, Carolyn Horton, Min-Tzu Lo, Linda Polfus, Cassidy Carraway, Parichehr Hemyari, Colin Young, Marcy E. Richardson, Rochelle Scheib, Judy E. Garber, Huma Q. Rana
    Genetics in Medicine Open.2024; 2: 101829.     CrossRef
  • Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial
    Christopher Grisham, Beth N. Peshkin, Lia Sorgen, Claudine Isaacs, Mary Kathleen Ladd, Aryana Jacobs, Savannah Binion, Mara Tynan, Emily Kuchinsky, Susan Friedman, Kathryn L. Taylor, Kristi Graves, Suzanne O’Neill, David Kim, Marc D. Schwartz
    Public Health Genomics.2024; 27(1): 100.     CrossRef
  • Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis
    Muhammad Danyal Ahsan, Isabelle R. Chandler, Samantha Min, Benjamin Grant, Michelle Primiano, Jamieson Greenwald, Tamar N. Soussana, Becky Baltich Nelson, Charlene Thomas, Eloise Chapman-Davis, Ravi N. Sharaf, Melissa K. Frey
    Clinical Obstetrics & Gynecology.2024; 67(4): 702.     CrossRef
  • Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics
    Brittany L. Bychkovsky, Min‐Tzu Lo, Amal Yussuf, Carrie Horton, Marcy Richardson, Holly LaDuca, Judy E. Garber, Huma Q. Rana
    Cancer.2022; 128(6): 1275.     CrossRef
  • Health equity in the implementation of genomics and precision medicine: A public health imperative
    Muin J. Khoury, Scott Bowen, W. David Dotson, Emily Drzymalla, Ridgely F. Green, Robert Goldstein, Katherine Kolor, Leandris C. Liburd, Laurence S. Sperling, Rebecca Bunnell
    Genetics in Medicine.2022; 24(8): 1630.     CrossRef
  • Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis
    Melissa K. Frey, Muhammad Danyal Ahsan, Hannah Bergeron, Jenny Lin, Xuan Li, Rana K. Fowlkes, Priyanka Narayan, Roni Nitecki, Jose Alejandro Rauh-Hain, Haley A. Moss, Becky Baltich Nelson, Charlene Thomas, Paul J. Christos, Jada G. Hamilton, Eloise Chapma
    Journal of Clinical Oncology.2022; 40(35): 4129.     CrossRef
  • Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
    Brittany L. Bychkovsky, Nihat B. Agaoglu, Carolyn Horton, Jing Zhou, Amal Yussuf, Parichehr Hemyari, Marcy E. Richardson, Colin Young, Holly LaDuca, Deborah L. McGuinness, Rochelle Scheib, Judy E. Garber, Huma Q. Rana
    JAMA Oncology.2022; 8(11): 1598.     CrossRef
  • 6,091 View
  • 148 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Cervical Cancer Screening Rate and Willingness among Female Migrants in Shenzhen, China: Three-Year Changes in Citywide Surveys
Wei Lin, Bin Chen, Bo Wu, Shixin Yuan, Chuyan Zhong, Weikang Huang, Haiyan Hu, Zhihua Liu, Yueyun Wang
Cancer Res Treat. 2021;53(1):212-222.   Published online September 1, 2020
DOI: https://doi.org/10.4143/crt.2020.219
AbstractAbstract PDFPubReaderePub
Purpose
This study attempted to detect the changes of cervical cancer screening rate and willingness among female migrants, and the associated socio-demographic factors in Shenzhen city.
Materials and Methods
Two citywide surveys were conducted using a multistage random cluster sampling method in 2011 and 2014, respectively. Data on demographic characteristics, screening participation, and willingness to screen were collected. Logistic regression models were applied to detect possible associated socio-demographic characteristics, and their variations with survey years.
Results
In total, 12,017 female migrants were enrolled, with a mean age (standard deviation) of 36.73 (6.55) years. From 2011 to 2014, the screening rate increased (25.8% vs. 35.1%, p < 0.001), while the willingness to screen remained stable (82.2% vs. 82.8%, p=0.46). Overall, socio-demographic characteristics of female migrants, including age, marital status, education, monthly income, employment, and medical insurance, were found to be positively associated with screening participation. Similar impacts in relation to willingness were observed except for age. However, these associations varied with survey years, mainly in the contributions of education and monthly income to screening participation, as well as age, monthly income, and medical insurance to willingness of being screened.
Conclusion
Identifying changes of associated socio-demographic factors precisely is warranted of necessity, which provides novel clues to adjust targeted actions regularly in promoting cervical cancer screening participation among female migrants in Shenzhen.

Citations

Citations to this article as recorded by  
  • Using planned behavior theory to understand cervical cancer screening intentions in Chinese women
    Tingting Xin, Yuting Jiang, Chunting Li, Xian Ding, Zhu Zhu, Xiao Chen
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Associations between the signing status of family doctor contract services and cervical cancer screening behaviors: a cross-sectional study in Shenzhen, China
    Wei Lin, Weikang Huang, Chaofan Mei, Peiyi Liu, He Wang, Shixin Yuan, Xiaoshan Zhao, Yueyun Wang
    BMC Public Health.2023;[Epub]     CrossRef
  • Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status
    Mengyin Ao, Xiaoxi Yao, Danxi Zheng, Xuesai Gu, Mingrong Xi
    Infectious Agents and Cancer.2023;[Epub]     CrossRef
  • Populations at high risk of cervical cancer in Guangxi Province: Findings from two screening projects in a minority area of South China
    Huaxiang Lu, Haoyu He, Jian Qin, Mingjian Chen, Qiumei Liu, Min Li, Yongsheng Huang, Anxiang Wei, Shuzhen Liu, Min Xu, Zhiyong Zhang
    Journal of Medical Screening.2022; 29(1): 44.     CrossRef
  • Willingness to utilize cervical cancer screening among Ethiopian women aged 30–65 years
    Adugna Alemu Desta, Fikadu Tolesa Alemu, Moges Beya Gudeta, Dejene Edosa Dirirsa, Andualem Gezahegn Kebede
    Frontiers in Global Women's Health.2022;[Epub]     CrossRef
  • Status quo and problem analysis of cervical cancer screening program in China: Based on RE-AIM framework
    Jingfen Zhu, Zhenghao Ge, Jiawei Xia, Qi Liu, Qingqing Ran, Yongbin Yang
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • 6,468 View
  • 113 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Adherence to Cancer Prevention Guidelines and Endometrial Cancer Risk: Evidence from a Systematic Review and Dose-Response Meta-analysis of Prospective Studies
Hui Sun, Qing Chang, Ya-Shu Liu, Yu-Ting Jiang, Ting-Ting Gong, Xiao-Xin Ma, Yu-Hong Zhao, Qi-Jun Wu
Cancer Res Treat. 2021;53(1):223-232.   Published online September 14, 2020
DOI: https://doi.org/10.4143/crt.2020.546
AbstractAbstract PDFPubReaderePub
Purpose
The evidence of adherence to cancer prevention guidelines and endometrial cancer (EC) risk has been limited and controversial. This study summarizes and quantifies the relationship between adherence to cancer prevention guidelines and EC risk.
Materials and Methods
The online databases PubMed, Web of Science, and EMBASE were searched for relevant publications up to June 2, 2020. This study had been registered at PROSPERO. The registration number is CRD42020149966. Study quality evaluation was performed based on the Newcastle-Ottawa Scale. The I2 statistic was used to estimate heterogeneity among studies. Egger’s and Begg’s tests assessed potential publication bias. Summary hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationship between adherence to cancer prevention guidelines score was assigned to participants by summarizing individual scores for each lifestyle-related factor. The scores ranged from least healthy (0) to most healthy (20) and the EC risk was calculated using a randomeffects model.
Results
Five prospective studies (four cohort studies and one case‑cohort study) consisted of 4,470 EC cases, where 597,047 participants were included. Four studies had a low bias risk and one study had a high bias risk. Summary EC HR for the highest vs. lowest score of adherence to cancer prevention guidelines was 0.54 (95% CI, 0.40 to 0.73) and had a high heterogeneity (I2=86.1%). For the dose-response analysis, an increment of 1 significantly reduced the risk of EC by 6%. No significant publication bias was detected.
Conclusion
This study suggested that adherence to cancer prevention guidelines was negatively related to EC risk.

Citations

Citations to this article as recorded by  
  • Expression of EMT-related genes in lymph node metastasis in endometrial cancer: a TCGA-based study
    He Li, Junzhu Wang, Liwei Li, Luyang Zhao, Zhiqi Wang
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Advances on Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward?
    Andrea Giannini, Giorgio Bogani, Enrico Vizza, Vito Chiantera, Antonio Simone Laganà, Ludovico Muzii, Maria Giovanna Salerno, Donatella Caserta, Ottavia D’Oria
    Healthcare.2022; 10(9): 1605.     CrossRef
  • 7,089 View
  • 144 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
A Preoperative Nomogram for Predicting Chemoresistance to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Squamous Carcinoma Treated with Radical Hysterectomy
Zhengjie Ou, Dan Zhao, Bin Li, Yating Wang, Shuanghuan Liu, Yanan Zhang
Cancer Res Treat. 2021;53(1):233-242.   Published online September 14, 2020
DOI: https://doi.org/10.4143/crt.2020.159
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to investigate the factors associated with chemoresistance to neoadjuvant chemotherapy (NACT) followed by radical hysterectomy (RH) and construct a nomogram to predict the chemoresistance in patients with locally advanced cervical squamous carcinoma (LACSC).
Materials and Methods
This retrospective study included 516 patients with International Federation of Gynecology and Obstetrics (2003) stage IB2 and IIA2 cervical cancer treated with NACT and RH between 2007 and 2017. Clinicopathologic data were collected, and patients were assigned to training (n=381) and validation (n=135) sets. Univariate and multivariate analyses were performed to analyze factors associated with chemoresistance to NACT. A nomogram was built using the multivariate logistic regression analysis results. We evaluated the discriminative ability and accuracy of the model using a concordance index and a calibration curve. The predictive probability of chemoresistance to NACT was defined as > 34%.
Results
Multivariate analysis confirmed menopausal status, clinical tumor diameter, serum squamous cell carcinoma antigen level, and parametrial invasion on magnetic resonance imaging before treatment as independent prognostic factors associated with chemoresistance to NACT. The concordance indices of the nomogram for training and validation sets were 0.861 (95% confidence interval [CI], 0.822 to 0.900) and 0.807 (95% CI, 0.807 to 0.888), respectively. Calibration plots revealed a good fit between the modelpredicted probabilities and actual probabilities (Hosmer-Lemeshow test, p=0.597). Furthermore, grouping based on the nomogram was associated with progression-free survival.
Conclusion
We developed a nomogram for predicting chemoresistance in LACSC patients treated with RH. This nomogram can help physicians make clinical decisions regarding primary management and postoperative follow-up of the patients.

Citations

Citations to this article as recorded by  
  • Are biomarkers expression and clinical-pathological factors predictive markers of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer?
    Antonino Ditto, Mariangela Longo, Giulia Chiarello, Luigi Mariani, Biagio Paolini, Umberto Leone Roberti Maggiore, Fabio Martinelli, Giorgio Bogani, Francesco Raspagliesi
    European Journal of Surgical Oncology.2024; 50(6): 108311.     CrossRef
  • A Deep Learning Radiomics Nomogram to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer: A Two-Center Study
    Yajiao Zhang, Chao Wu, Zhibo Xiao, Furong Lv, Yanbing Liu
    Diagnostics.2023; 13(6): 1073.     CrossRef
  • Machine Learning-Assisted Ensemble Analysis for the Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
    Yibao Huang, Qingqing Zhu, Liru Xue, Xiaoran Zhu, Yingying Chen, Mingfu Wu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 5,514 View
  • 124 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
Impact of the Learning Curve on the Survival of Abdominal or Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
Lan Ying Li, Lan Ying Wen, Sun Hee Park, Eun Ji Nam, Jung Yun Lee, Sunghoon Kim, Young Tae Kim, Sang Wun Kim
Cancer Res Treat. 2021;53(1):243-251.   Published online October 12, 2020
DOI: https://doi.org/10.4143/crt.2020.063
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The objective of this study was to define the learning curve required to attain satisfactory oncologic outcomes of cervical cancer patients who were undergoing open or minimally invasive surgery for radical hysterectomy, and to analyze the correlation between the learning curve and tumor size.
Materials and Methods
Cervical cancer patients (stage IA-IIA) who underwent open radical hysterectomy (n=280) or minimal invasive radical hysterectomy (n=282) were retrospectively reviewed. The learning curve was evaluated using cumulative sum of 5-year recurrence rates. Survival outcomes were analyzed based on the operation period (“learning period,” P1 vs. “skilled period,” P2), operation mode, and tumor size.
Results
The 5-year disease-free and overall survival rates between open and minimally invasive groups were 91.8% and 89.0% (p=0.098) and 96.1% and 97.2% (p=0.944), respectively. The number of surgeries for learning period was 30 and 60 in open and minimally invasive group, respectively. P2 had better 5-year disease-free survival than P1 after adjusting for risk factors (hazard ratio, 0.392; 95% confidence interval, 0.210 to 0.734; p=0.003). All patients with tumors < 2 cm had similar 5-year disease-free survival regardless of operation mode or learning curve. Minimally invasive group presented lower survival rates than open group when tumors ≥ 2 cm in P2. Preoperative conization improved disease-free survival in patients with tumors ≥ 2 cm, especially in minimally invasive group.
Conclusion
Minimally invasive radical hysterectomy required more cases than open group to achieve acceptable 5-year disease-free survival. When tumors ≥ 2 cm, the surgeon’s proficiency affected survival outcomes in both groups.

Citations

Citations to this article as recorded by  
  • Radical Hysterectomy With Preoperative Conization in Early-Stage Cervical Cancer: A Systematic Review and Pairwise and Network Meta-Analysis
    Xinbin Zhu, Lele Ye, Yunfeng Fu, Bingbing You, Weiguo Lu
    Journal of Minimally Invasive Gynecology.2024; 31(3): 193.     CrossRef
  • Minimally invasive radical hysterectomy and the importance of avoiding cancer cell spillage for early-stage cervical cancer: a narrative review
    Atsushi Fusegi, Hiroyuki Kanao, Shiho Tsumura, Atsushi Murakami, Akiko Abe, Yoichi Aoki, Hidetaka Nomura
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy
    Nicolò Bizzarri, Lukáš Dostálek, Luc R. C. W. van Lonkhuijzen, Diana Giannarelli, Aldo Lopez, Henrik Falconer, Denis Querleu, Ali Ayhan, Sarah H. Kim, David Isla Ortiz, Jaroslav Klat, Fabio Landoni, Juliana Rodriguez, Ranjit Manchanda, Jan Kosťun, Pedro T
    Obstetrics & Gynecology.2023; 141(1): 207.     CrossRef
  • Learning Laparoscopic Radical Hysterectomy: Are We Facing an Emerging Situation?
    Graziella Moufawad, Antonio Simone Laganà, Nassir Habib, Vito Chiantera, Andrea Giannini, Federico Ferrari, Amerigo Vitagliano, Luigi Della Corte, Giuseppe Bifulco, Zaki Sleiman
    International Journal of Environmental Research and Public Health.2023; 20(3): 2053.     CrossRef
  • Breast Reconstruction with DIEP Flap: The Learning Curve at a Breast Reconstruction Center and a Single-Surgeon Study
    Charalampos Varnava, Philipp Wiebringhaus, Tobias Hirsch, Alexander Dermietzel, Maximilian Kueckelhaus
    Journal of Clinical Medicine.2023; 12(8): 2894.     CrossRef
  • A meta-analysis of survival after minimally invasive radical hysterectomy versus abdominal radical hysterectomy in cervical cancer: center-associated factors matter
    Si Sun, Jing Cai, Ruixie Li, Yujia Wang, Jing Zhao, Yuhui Huang, Linjuan Xu, Qiang Yang, Zehua Wang
    Archives of Gynecology and Obstetrics.2022; 306(3): 623.     CrossRef
  • Comparison of Minimally Invasive Versus Abdominal Radical Hysterectomy for Early-Stage Cervical Cancer: An Updated Meta-Analysis
    Mengting Zhang, Wei Dai, Yuexiu Si, Yetan Shi, Xiangyuan Li, Ke Jiang, Jingyi Shen, Liying Ying
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Assessment of ESGO Quality Indicators in Cervical Cancer Surgery: A Real-World Study in a High-Volume Chinese Hospital
    Yan Ding, Xuyin Zhang, Junjun Qiu, Jianfeng Zhang, Keqin Hua
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in Surgical Morbidity and Survival Outcomes for Radical Hysterectomy in West China: An 11-Year Retrospective Cohort Study
    Huining Jing, Ying Yang, Yinxia Liu, Peijun Zou, Zhengyu Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Comparison of Prognosis between Minimally Invasive and Abdominal Radical Hysterectomy for Patients with Early-Stage Cervical Cancer
    Tomohito Tanaka, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Shinichi Terada, Hiromi Konishi, Yuhei Kogata, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
    Current Oncology.2022; 29(4): 2272.     CrossRef
  • Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma
    Yeorae Kim, Se Ik Kim, Hyojin Kim, Maria Lee, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Yong Beom Kim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Cheol Lee, Dong Hoon Suh
    Gynecologic Oncology.2022; 167(1): 28.     CrossRef
  • Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer
    Fuyun Zhang, Xiaomei Song
    American Journal of Clinical Oncology.2022; 45(11): 465.     CrossRef
  • Surgical Approach and Use of Uterine Manipulator Are Not Associated with LVSI in Surgery for Early-stage Cervical Cancer
    Yinxia Liu, Shuying Huang, Xiu Ming, Huining Jing, Zhengyu Li
    Journal of Minimally Invasive Gynecology.2021; 28(9): 1573.     CrossRef
  • Minimally Invasive Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-analysis
    Anna Jo Bodurtha Smith, Tiffany Nicole Jones, Diana Miao, Amanda Nickles Fader
    Journal of Minimally Invasive Gynecology.2021; 28(3): 544.     CrossRef
  • The Surgeon’s Proficiency Affected Survival Outcomes of Minimally Invasive Surgery for Early-Stage Cervical Cancer: A Retrospective Study of 851 Patients
    Ying Yang, Yue Huang, Zhengyu Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • MicroRNA-300 Inhibits the Proliferation and Metastasis of Cervical Cancer Cells via Posttranscriptional Suppression of G Protein-Coupled Receptor 34 (GPR34)
    Mei Wang, Ying Tian, Lin Miao, Wenxia Zhao, Antonio Raffone
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • 6,986 View
  • 142 Download
  • 16 Crossref
Close layer
Pediatric cancer
The Broad Variability in Dental Age Observed among Childhood Survivors Is Cancer Specific
Patrycja Proc, Joanna Szczepańska, Małgorzata Zubowska, Beata Zalewska-Szewczyk, Wojciech Młynarski
Cancer Res Treat. 2021;53(1):252-260.   Published online August 24, 2020
DOI: https://doi.org/10.4143/crt.2020.275
AbstractAbstract PDFPubReaderePub
Purpose
The study aimed to assess the differences in dental maturation between childhood cancer survivors and healthy children.
Materials and Methods
Fifty-nine cancer patients including 16 (27.1%) girls and 43 (72.8%) boys, aged between 4 and 16 years, underwent dental and radiographic examinations. The mean duration of anticancer therapy was 16.8 months (range, 1 to 47 months), and 4.6 years (range, 8 to 123 months) had passed since the termination of disease. The control group consisted of 177 panoramic radiographs of age- and sex-matched healthy individuals. Dental age (DA) was estimated with Demirjian’s scale and delta age, i.e., DA–chronological age (CA), was used to compare groups.
Results
The DA of cancer survivors was accelerated by almost 1 year compared to their CA (9.9±3.1 vs. 8.9±2.8, p=0.040). The greatest difference was observed among patients with brain tumor: delta (DA–CA) was 2.2±1.1 years. Among all cancer patients, only children with familial adenomatous polyposis (FAP)-associated hepatoblastoma (HP) demonstrated delayed DA, with regard to both other cancer survivors (p=0.011) and healthy patients (p=0.037). All four patients with HP suffered from FAP, and three of them had documented adenomatous polyposis coli (APC) genes mutation. The DA of cancer patients having teeth with short roots was significantly greater than that of the cancer survivors without this anomaly (12.8±3.2 vs. 9.0±2.4, p < 0.001).
Conclusion
DA in children may be altered by cancer disease.

Citations

Citations to this article as recorded by  
  • Dental management of long-term childhood cancer survivors: a systematic review
    K. Seremidi, S. Gizani, G. Dahllöf, M. Barr-Agholme, D. Kloukos, G. Tsilingaridis
    European Archives of Paediatric Dentistry.2024; 25(5): 611.     CrossRef
  • Dental age estimation in children that have undergone antineoplastic treatment
    A. Mitsea, K. Seremidi, A. Tsiligianni, S. Gizani
    European Archives of Paediatric Dentistry.2022; 23(2): 243.     CrossRef
  • Comparative Study of Malocclusions between Cancer Patients and Healthy Peers
    Patrycja Proc, Joanna Szczepanska, Anna Herud, Malgorzata Zubowska, Wojciech Fendler, Monika Lukomska-Szymanska, Wojciech Mlynarski
    International Journal of Environmental Research and Public Health.2022; 19(7): 4045.     CrossRef
  • 6,672 View
  • 104 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
Ying Yang, Dong Wang, Lei Cui, Hong-Hao Ma, Li Zhang, Hong-Yun Lian, Qing Zhang, Xiao-Xi Zhao, Li-Ping Zhang, Yun-Ze Zhao, Na Li, Tian-You Wang, Zhi-Gang Li, Rui Zhang
Cancer Res Treat. 2021;53(1):261-269.   Published online September 15, 2020
DOI: https://doi.org/10.4143/crt.2020.769
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.

Citations

Citations to this article as recorded by  
  • Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
    Emmanuel Lee Boniao, Richard C. Allen, Gangadhara Sundar
    Orbit.2024; 43(5): 656.     CrossRef
  • Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
    Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study
    Jiaying Lei, Wenxia Wang, Danna Lin, Chengguang Zhu, Wenguang Jia, Wenjun Weng, Xiaoshan Liu, Yuhan Ma, Zhixuan Wang, Lihua Yang, Xiangling He, Yunyan He, Yang LI
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis
    Xinshun Ge, Wenxin Ou, Ang Wei, Hongyun Lian, Honghao Ma, Lei Cui, Dong Wang, Liping Zhang, Xiaoman Wang, Lejian He, Rui Zhang, Tianyou Wang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
    Isaac Hauk, Ignacio Gonzalez‐Gomes, Deepak Chellapandian, Jonathan Metts, Peter H. Shaw
    Pediatric Blood & Cancer.2024;[Epub]     CrossRef
  • Advancements in the understanding and management of histiocytic neoplasms
    Kyung-Nam Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im
    Blood Research.2024;[Epub]     CrossRef
  • Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
    Paul G. Kemps, F. J. Sherida H. Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A. G. Meyer-Wentrup, Natasja Dors, Natasha K. A. van Eijkelenburg, Marijn A. Scheijde-Vermeulen, Ingrid M. Jazet, Maarten Limper, Margot Jak,
    Blood Neoplasia.2024; 1(3): 100023.     CrossRef
  • The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis
    Zi-Jing Zhao, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Ting Zhu, Hua-Lin Li, Xiao-Tong Huang, Tian-You Wang, Rui Zhang, Lei Cui, Zhi-Gang Li
    Jornal de Pediatria.2024;[Epub]     CrossRef
  • Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system
    Evgeniy F. Khynku, Maria K. Monaenkova, Olga B. Tamrazova, Alexey V. Taganov, Мarina А. Gureeva, Gayane E. Bagramova, Anton V. Molochkov
    Almanac of Clinical Medicine.2023; 50(7): 428.     CrossRef
  • Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis
    Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, M
    Blood Advances.2023; 7(10): 2171.     CrossRef
  • Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
    Ashley V. Geerlinks, Oussama Abla
    Pediatric Drugs.2023; 25(4): 399.     CrossRef
  • Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
    James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
    Blood Advances.2023; 7(15): 3806.     CrossRef
  • Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
    Anke Elisabeth Barnbrock, Caroline Hutter, Konrad Bochennek, Milen Minkov, Thomas Lehrnbecher
    Klinische Pädiatrie.2023; 235(06): 342.     CrossRef
  • Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
    Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, Mariko Yabe, Young Rock Chung, Gilad Itchaki, Maayan Ben-Sasson, Vered A. Asher-Guz, David Groshar, Seyram A. Doe-Tetteh, Tina Alano, David B. Solit, Ofer Shpilberg, Eli L. Diamond, Roei D. M
    Blood Advances.2023; 7(23): 7319.     CrossRef
  • Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations
    Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
    Pharmaceutics.2023; 16(1): 5.     CrossRef
  • Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
    Oussama Abla
    Hematology.2023; 2023(1): 386.     CrossRef
  • Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement
    Ja-Feng Yao, Dong Wang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Tian-You Wang, Zhi-Gang Li, Jin Jiang, Lei Cui, Rui Zhang
    The Journal of Pediatrics.2022; 244: 194.     CrossRef
  • Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis
    Dong Wang, Xi-Hua Chen, Ang Wei, Chun-Ju Zhou, Xue Zhang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Qing Zhang, Xiao-Tong Huang, Chan-Juan Wang, Ying Yang, Wei Liu, Tian-You Wang, Zhi-Gang Li, Lei Cui, Rui Zhang
    Orphanet Journal of Rare Diseases.2022;[Epub]     CrossRef
  • Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review
    Jagadeesh Menon, Ashwin Rammohan, Mukul Vij, Naresh Shanmugam, Mohamed Rela
    World Journal of Gastroenterology.2022; 28(30): 4044.     CrossRef
  • Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
    延泽 刘
    Advances in Clinical Medicine.2022; 12(09): 8499.     CrossRef
  • Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis
    Jin Kyung Suh, Sunghan Kang, Hyery Kim, Ho Joon Im, Kyung-Nam Koh
    BLOOD RESEARCH.2021; 56(S1): S65.     CrossRef
  • Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement


    Ying Yang, Dong Wang, Na Li, Honghao Ma, Hongyun Lian, Lei Cui, Qing Zhang, Xiaoxi Zhao, Liping Zhang, Yunze Zhao, Chanjuan Wang, Li Zhang, Tianyou Wang, Zhigang Li, Rui Zhang
    OncoTargets and Therapy.2020; Volume 13: 12357.     CrossRef
  • 34,571 View
  • 227 Download
  • 17 Web of Science
  • 22 Crossref
Close layer
Lymphoma
Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
Hee Sang Hwang, Meejeong Kim, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh, Heounjeong Go
Cancer Res Treat. 2021;53(1):270-278.   Published online September 15, 2020
DOI: https://doi.org/10.4143/crt.2020.626
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In contrast to the Western diffuse large B-cell lymphoma (DLBCL), prognostic impact of age in a Korean population with DLBCL has not been fully evaluated.
Materials and Methods
Six hundred and eight DLBCL patients treated with rituximab-containing chemotherapeutic regimens from January 2002 to March 2012 in Asan Medical Center were enrolled. Survival models using the restricted cubic spine−transformed age variable were constructed to evaluate non-linear relationships between age and survival outcome. Finally, age was categorized according to the conventional international prognostic index (IPI), National Comprehensive Cancer Network (NCCN)-IPI, and Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GELTAMO)-IPI schemes and the prognostic implications were evaluated.
Results
The relative hazard did not change significantly during the first to fifth decades, but began to increase exponentially in patients aged over 62 years. This pattern or relationship was also retained in a multivariate model fitted to the age-adjusted IPI and relative dose intensity. Multivariate survival analysis revealed that age > 75 years, but not age > 60 years, was associated independently with poor overall and progression-free survival when the relative dose intensity and age-adjusted IPI were taken into account.
Conclusion
The outcome of DLBCL in Korean populations may deteriorate rapidly as age exceeds 62 years. Therefore, a consensus cutoff value for age in Korean DLBCL patients should be determined to better predict prognosis.

Citations

Citations to this article as recorded by  
  • Two distinct age-prognosis patterns in patients with esophageal cancer undergoing surgical and radiotherapy treatments: a combined analysis of 3JECROG and SEER databases
    Chen Li, Xiao Chang, Qifeng Wang, Qingsong Pang, Zefen Xiao, Wencheng Zhang, Zhiyong Yuan
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
    Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
    Blood Advances.2021; 5(9): 2426.     CrossRef
  • 6,872 View
  • 110 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Case Reports
Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
Marco Focaccia, Marco Gambarotti, Rossella Hakim, Anna Paioli, Marilena Cesari, Benedetta Spazzoli, Paolo Spinnato, Davide Donati, Michele Rocca, Alessandra Longhi
Cancer Res Treat. 2021;53(1):279-282.   Published online August 6, 2020
DOI: https://doi.org/10.4143/crt.2020.384
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Chondroblastoma is a rare benign chondrogenic tumor that occurs in skeletally immature patients between ages 10 and 20 years old. In literature are reported few cases of lung metastases, mainly occurred after surgery or local recurrences. There is no evidence on the pathogenesis of lung metastasis, as well as pulmonary disease course. Few treatments for metastases with aggressive behavior were based on chemotherapy regimen employed in other sarcoma with no results or not satisfying ones. Denosumab is approved for treatment of giant cell tumors and it is under investigation for other giant cell-rich bone tumors. Here, we report a case of a 16-year-old male chondroblastoma of the left humerus with bilateral lung metastases at presentation and progressing during follow-up, treated with denosumab for almost 2 years. We confirm that denosumab treatment can be effective in controlling chondroblastoma metastasis and it has been a safe procedure in an adolescent patient.

Citations

Citations to this article as recorded by  
  • 3D Specimen Scanning and Mapping in Musculoskeletal Oncology: A Feasibility Study
    Juan M. Colazo, Kavita Prasad, Alexis Miller, Kayvon Sharif, Marina Aweeda, Carly Fassler, Reena Singh, Herbert S. Schwartz, Joshua M. Lawrenz, Ginger E. Holt, Michael C. Topf
    Annals of Surgical Oncology.2024; 31(3): 2051.     CrossRef
  • Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches
    Ramy Samargandi, Abrar Bafail, Louis-Romée Le Nail, Julien Berhouet
    Cancers.2024; 16(12): 2283.     CrossRef
  • Chondroblastoma Affecting the Apophysis of the Greater Trochanter in a Child
    Svetoslav A Slavchev, Philip J O'Connor, Georgi P Georgiev
    Cureus.2023;[Epub]     CrossRef
  • Recurrent chondroblastoma of the talus: A case report and literature review of recurrent lesions in the foot and ankle
    Olivia Jagiella-Lodise, Timothy McAleese, Mark Curtin, Alan Molloy, James Walsh
    International Journal of Surgery Case Reports.2023; 106: 108192.     CrossRef
  • Huge Chondroblastoma of the Talus: A Case Report
    Sung Hyun Yoon, Hyun-woo Park
    Journal of Korean Foot and Ankle Society.2023; 27(4): 154.     CrossRef
  • A Rare Case of Chondroblastoma from Neolithic Crete of the 7th Millennium BCE
    Anagnostis P. Agelarakis, Lisa M. DiFrancesco, Lukas Delasos, Julian Samodulski, Athanasia Kanta, Panayotis G. Agelarakis
    Paléorient.2023; (49-1): 229.     CrossRef
  • Pulmonary Metastases of Chondroblastoma in a Pediatric Patient: A Case Report and Review of Literature
    Courtney Wing, Pankaj Watal, Monica Epelman, Juan Infante, Tushar Chandra
    Cureus.2022;[Epub]     CrossRef
  • 5,665 View
  • 131 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers
Jeong-Seon Lee, Hye Young Jin, Jung Min Ko, Seoung Hoon Kim, Nayoung Han, Byung Kiu Park, Meerim Park, Hyeon Jin Park, Jun Ah Lee
Cancer Res Treat. 2021;53(1):283-288.   Published online September 7, 2020
DOI: https://doi.org/10.4143/crt.2020.575
AbstractAbstract PDFPubReaderePub
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.

Citations

Citations to this article as recorded by  
  • Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies
    Marco F. Moedas, Ricardo J.M. Simões, Margarida F.B. Silva
    Biochemical Pharmacology.2024; 222: 116034.     CrossRef
  • Fibroadenoma Intracanalicular Hipercelular: uma revisão de literatura e relato de 5 casos
    Isadora Benevides Silva Gondim Nascimento, Roberta Pereira Guerra Pedra, Amanda Veloso Teixeira, Maria Isabel Teles Nogueira, Kaio Henrique Oliveira Pontes
    Journal Archives of Health.2024; 5(3): e1860.     CrossRef
  • Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
    Solomon N. Levin, Michael D. Tomasini, James Knox, Mahsa Shirani, Bassem Shebl, David Requena, Jackson Clark, Søren Heissel, Hanan Alwaseem, Rodrigo Surjan, Ron Lahasky, Henrik Molina, Michael S. Torbenson, Barbara Lyons, Rachael D. Migler, Philip Coffino
    Science Advances.2023;[Epub]     CrossRef
  • WITHDRAWN: Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
    Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
    Current Problems in Cancer: Case Reports.2022; : 100141.     CrossRef
  • Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
    Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
    Current Problems in Cancer.2022; 46(3): 100847.     CrossRef
  • Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias
    Teodoro Jerves, Nenad Blau, Carlos R. Ferreira
    Molecular Genetics and Metabolism.2022; 136(2): 118.     CrossRef
  • Paraneoplastic syndromes in hepatocellular carcinoma: a review
    Yuki Ong, Cheong Wei Terence Huey, Vishalkumar Girishchandra Shelat
    Expert Review of Gastroenterology & Hepatology.2022; 16(5): 449.     CrossRef
  • Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment
    Kena Song, Zhangqing Yu, Xiangyang Zu, Guoqiang Li, Zhigang Hu, Yun Xue
    International Journal of Molecular Sciences.2022; 23(18): 10509.     CrossRef
  • Fibrolamellar carcinoma: An entity all its own
    Allison F. O'Neill, Alanna J. Church, Antonio R. Perez-Atayde, Raja Shaikh, Karen J. Marcus, Khashayar Vakili
    Current Problems in Cancer.2021; 45(4): 100770.     CrossRef
  • Severe digital ischemia coexists with thrombocytopenia in malignancy-associated antiphospholipid syndrome: A case report and review of literature
    Jia-Lei Chen, Xi Yu, Rong Luo, Ming Liu
    World Journal of Clinical Cases.2021; 9(36): 11457.     CrossRef
  • Antineoplastics/sodium-benzoate

    Reactions Weekly.2020; 1825(1): 46.     CrossRef
  • 6,567 View
  • 188 Download
  • 9 Web of Science
  • 11 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP